<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Inflamm Regen</journal-id><journal-id journal-id-type="iso-abbrev">Inflamm Regen</journal-id><journal-title-group><journal-title>Inflammation and Regeneration</journal-title></journal-title-group><issn pub-type="ppub">1880-9693</issn><issn pub-type="epub">1880-8190</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5725926</article-id><article-id pub-id-type="publisher-id">14</article-id><article-id pub-id-type="doi">10.1186/s41232-016-0014-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>GM-CSF as a therapeutic target in autoimmune diseases</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Shiomi</surname><given-names>Aoi</given-names></name><address><phone>+81-75-753-3793</phone><fax>+81-75-753-4338</fax><email>ashiomi@kuhp.kyoto-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Usui</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mimori</surname><given-names>Tsuneyo</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.258799.8</institution-id><institution-id institution-id-type="ISNI">0000000403722033</institution-id><institution>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, </institution><institution>Kyoto University, </institution></institution-wrap>54-Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507 Japan </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>36</volume><elocation-id>8</elocation-id><history><date date-type="received"><day>1</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>&#169; Shiomi et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access </bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been known as a hematopoietic growth factor and immune modulator. Recent studies revealed that GM-CSF also had pro-inflammatory functions and contributed to the pathogenicity of Th17 cells in the development of Th17-mediated autoimmune diseases. GM-CSF inhibition in some animal models of autoimmune diseases showed significant beneficial effects. Therefore, several agents targeting GM-CSF are being developed and are expected to be a useful strategy for the treatment of autoimmune diseases. Particularly, in clinical trials for rheumatoid arthritis (RA) patients, GM-CSF inhibition showed rapid and significant efficacy with no serious side effects. This article summarizes recent findings of GM-CSF and information of clinical trials targeting GM-CSF in autoimmune diseases.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>GM-CSF</kwd><kwd>IL-17</kwd><kwd>Autoimmune disease</kwd><kwd>Multiple sclerosis</kwd><kwd>Rheumatoid arthritis</kwd><kwd>Crohn&#8217;s disease</kwd><kwd>Th17 plasticity</kwd><kwd>GM-CSF target therapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par14">Granulocyte-macrophage colony-stimulating factor (GM-CSF) was originally defined by its ability in vivo to generate colonies of both granulocytes and macrophages from bone marrow precursors [<xref ref-type="bibr" rid="CR1">1</xref>]. It has also been shown to act on mature myeloid cells as pro-survival, activation, and differentiation factors [<xref ref-type="bibr" rid="CR2">2</xref>]. Recent studies suggest that GM-CSF also has many pro-inflammatory functions and plays critical roles in the development of autoimmune and inflammatory diseases [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p></sec><sec id="Sec2"><title>Function of GM-CSF</title><sec id="Sec3"><title>Myeloid cell</title><p id="Par15">GM-CSF promotes the survival and activation of macrophages, neutrophils, and eosinophils, as well as dendritic cell (DC) maturation [<xref ref-type="bibr" rid="CR2">2</xref>]. On the other hand, GM-CSF-deficient mice have relatively normal myelopoiesis with abnormal lung histology that is indistinguishable from human pulmonary alveolar proteinosis (PAP) [<xref ref-type="bibr" rid="CR5">5</xref>], indicating a redundant role of GM-CSF in myeloid cell development and its differentiation and critical roles in the maturation and surfactant catabolism of alveolar macrophages [<xref ref-type="bibr" rid="CR6">6</xref>]. In addition to these functions, GM-CSF is reported to have diverse functions on mature myeloid cells, including enhancement of pro-inflammatory cytokine production [<xref ref-type="bibr" rid="CR7">7</xref>], antigen presentation [<xref ref-type="bibr" rid="CR8">8</xref>], induction of phagocytosis [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>], and promotion of leukocyte chemotaxis and adhesion [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par16">GM-CSF can polarize macrophages into M1-like inflammatory macrophages, which produce a variety of inflammatory cytokines such as TNF, IL-6, IL-12p70, IL-23, or IL-1&#946;, and thus promote Th1-Th17 responses [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. On the other hand, the association of GM-CSF and Th2 immunity is also reported in allergic airway inflammation [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par17">GM-CSF positively regulates the development of dermal migratory CD103<sup>+</sup>CD11b<sup>&#8722;</sup> and gut migratory CD103<sup>+</sup>CD11b<sup>+</sup> DCs [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] but negatively regulates the development of plasmacytoid DCs (pDCs) [<xref ref-type="bibr" rid="CR20">20</xref>] and resident CD8<sup>+</sup> DCs [<xref ref-type="bibr" rid="CR19">19</xref>]. GM-CSF is also reported to induce the development of inflammatory monocyte-derived DCs (moDCs) in vitro [<xref ref-type="bibr" rid="CR21">21</xref>], but its effect in vivo has not been established well. It was reported that GM-CSF transgenic mice have increased the number of moDCs [<xref ref-type="bibr" rid="CR22">22</xref>] and GM-CSF-deficient mice with inflammatory arthritis have markedly reduced the number of moDCs [<xref ref-type="bibr" rid="CR23">23</xref>]. On the other hand, in the other reports, GM-CSF was shown to be dispensable for the differentiation of moDCs, at least during acute infections [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par18">In neutrophils, GM-CSF upregulates the antimicrobial functions such as phagocytosis, reactive oxygen species (ROS) production, or expression of the integrin CD11b which increases cellular adhesion and tissue entry [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par19">The effect of GM-CSF on osteoclast differentiation is quite complex, for it has both enhancing and suppressive actions. Under the steady state, osteoclasts are known to differentiate from hematopoietic precursors of the monocyte/macrophage lineage in the presence of M-CSF and receptor activator of NF&#954;B ligand (RANKL) [<xref ref-type="bibr" rid="CR26">26</xref>]. GM-CSF induces shedding of M-CSF receptor, resulting in disruption of osteoclast differentiation [<xref ref-type="bibr" rid="CR27">27</xref>]. On the other hand, the differentiation of osteoclast precursors generated in the presence of GM-CSF or GM-CSF plus TNF&#945; was not inhibited by GM-CSF in vitro, indicating that a different set of osteoclast precursors is available in inflammatory arthritis and that they respond to a variety of pro-inflammatory cytokines which compensate for the loss of M-CSF signaling [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. GM-CSF is also reported to induce fusion of prefusion osteoclasts to form the bone-resorbing osteoclasts and induce bone erosion [<xref ref-type="bibr" rid="CR30">30</xref>]. Conversely, other report suggested that GM-CSF inhibited the resorption ability of osteoclasts, indicating the existence of another osteoclastic pathway [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec4"><title>B cell</title><p id="Par20">Among B cells, innate response activator (IRA) B cells, a B1a B cell-derived inflammatory subset, produce GM-CSF and also express GM-CSF receptors [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. GM-CSF controls IgM production from IRA B cells in an autocrine manner which is essential to protect from bacterial infection [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec5"><title>Neuron</title><p id="Par21">Sensory nerves express GM-CSF receptors, and GM-CSF is reported as a key mediator in bone-cancer pain [<xref ref-type="bibr" rid="CR33">33</xref>], osteoarthritis pain, and inflammatory arthritic pain [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. A sensory nerve-specific knockdown of GM-CSF receptors attenuated tumor-evoked pain [<xref ref-type="bibr" rid="CR33">33</xref>]. GM-CSF deficiency or neutralization also abolished osteoarthritis pain and inflammatory arthritic pain [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].</p></sec></sec><sec id="Sec6"><title>GM-CSF receptor</title><p id="Par22">GM-CSF receptor consists of an &#945;-subunit which binds GM-CSF with low affinity (GMR&#945;) and a signal-transducing &#946;c-subunit which is shared with the IL-3 and IL-5 receptors [<xref ref-type="bibr" rid="CR36">36</xref>]. The binary complex of GM-CSF and GMR&#945; interacts with a free &#946;c-subunit and forms the high-affinity hexamer complex [<xref ref-type="bibr" rid="CR37">37</xref>]. Dodecamer complexes formed by lateral aggregation of two hexamer complexes enable Jak2 associated with a &#946;c-subunit to dimerize and transphosphorylate, but the hexamer complexes do not [<xref ref-type="bibr" rid="CR38">38</xref>]. This structure leads to dose-dependent responses of GM-CSF receptor activation. Low concentration of GM-CSF, as in normal condition, causes &#946;c Ser<sup>585</sup> phosphorylation and activates 14-3-3/PI-3 kinase pathway which only leads to cell survival. Higher concentration of GM-CSF, as in inflammatory condition, turns off &#946;c Ser<sup>585</sup> phosphorylation and mediated &#946;c Tyr<sup>577</sup> phosphorylation and activation of Jak2/STAT5 pathway, Ras/mitogen-activated protein kinase pathway, and PI-3 kinase pathway, resulting in promotion of cell survival, proliferation, and activation [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par23">The membrane-bound GM-CSF receptor is expressed on myeloid cells [<xref ref-type="bibr" rid="CR39">39</xref>] and on some non-myeloid cells, such as epithelial cells [<xref ref-type="bibr" rid="CR40">40</xref>], endothelial cells [<xref ref-type="bibr" rid="CR41">41</xref>], and neurons [<xref ref-type="bibr" rid="CR33">33</xref>]. There also exists a soluble GM-CSF receptor alpha subunit [<xref ref-type="bibr" rid="CR42">42</xref>]. The function of this soluble GM-CSF receptor is unclear, but it may be required to inhibit ligand binding to cells which express membrane-bound GM-CSF receptors [<xref ref-type="bibr" rid="CR43">43</xref>].</p></sec><sec id="Sec7"><title>Production of GM-CSF</title><p id="Par24">A wide variety of cells can produce GM-CSF. Major sources of GM-CSF are T and B cells, monocyte/macrophage endothelial cells, and fibroblasts. Neutrophils, eosinophils, epithelial cells, mesothelial cells, Paneth cells, chondrocytes, and tumor cells can also produce GM-CSF [<xref ref-type="bibr" rid="CR44">44</xref>]. The production of GM-CSF is stimulated by various factors, including TNF, IL-1, toll-like receptor agonists, and prostaglandin E2 [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Recently, the pathogenicity of GM-CSF-producing CD4 T cells in autoimmune and inflammatory diseases is clarified and gaining increasing attention [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par25">Recently, Th17 cells were clarified to have high plasticity [<xref ref-type="bibr" rid="CR47">47</xref>]. The &#8220;classical&#8221; Th17 cells driven by transforming growth factor-&#946;1 (TGF&#946;1) and IL-6 have been reported to be weak inducers of inflammation [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Conversely, IL-23 together with IL-1&#946; induces the differentiation of highly pathogenic Th17 cells (Th1/17 cells) which also express CXCR3 and T-bet and produce IL-17, IFN-&#947;, and GM-CSF in mice [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Recent studies clarified the production of GM-CSF is critical for the pro-inflammatory function of Th17 cells [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. In humans, IL-12, instead of IL-23, together with IL-1&#946; is reported to promote the differentiation of Th1/17 cells [<xref ref-type="bibr" rid="CR50">50</xref>]. Th1/17 cells can be distinguished from Th1 cells by the expression of CD161, a hallmark of Th17 progeny cells in humans [<xref ref-type="bibr" rid="CR51">51</xref>]. A recent study reported that IL-23 drives switch of surface signature from CCR6 to CCR2 which defines GM-CSF/IFN&#947;-producing inflammatory Th17 cells and that CCR2 drives these cells to the central nervous system (CNS) in experimental autoimmune encephalomyelitis (EAE) [<xref ref-type="bibr" rid="CR52">52</xref>]. The pathway to induce GM-CSF production in Th cells has not been clarified well yet. T-bet was reported to drive CCR6<sup>&#8722;</sup>CCR2<sup>+</sup> GM-CSF/IFN&#947;-producing Th17 cell formation [<xref ref-type="bibr" rid="CR52">52</xref>]. On the other hand, T-bet-deficient Th17 cells are reported to have normal GM-CSF production [<xref ref-type="bibr" rid="CR3">3</xref>]. Ectopic ROR&#947;t expression showed that ROR&#947;t drove GM-CSF production in Th cells [<xref ref-type="bibr" rid="CR4">4</xref>]. Conversely, ROR&#947;t-deficient CD4 T cells were also able to produce GM-CSF [<xref ref-type="bibr" rid="CR3">3</xref>]. These reports indicate the existence of additional pathways.</p><p id="Par26">GM-CSF is also reported to be produced by Th1 cells and is crucial for their encephalitogenicity [<xref ref-type="bibr" rid="CR4">4</xref>]. It was reported that STAT4 regulated GM-CSF production in Th1 cells but not in Th17 cells [<xref ref-type="bibr" rid="CR53">53</xref>]. On the other hand, the other report indicated that STAT4 regulated GM-CSF production in both Th1 and Th17 cells by directly binding to the Csf2 promoter [<xref ref-type="bibr" rid="CR54">54</xref>]. Recent findings on Th17 plasticity and heterogeneity indicate that it is necessary to re-examine previous studies in this field.</p><p id="Par27">In addition to these cells, recent studies reported the existence of an IL-2- or IL-7-activated STAT5-dependent novel subset of GM-CSF-producing Th cells (Th-GM) which express low or undetectable T-bet, GATA-3, or ROR&#947;t [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>] and that Th-GM cells were able to induce more severe EAE than Th17 or Th1 cells [<xref ref-type="bibr" rid="CR55">55</xref>]. In humans, the CCR10<sup>+</sup>CCR4<sup>+</sup>CXCR3<sup>&#8722;</sup>CCR6<sup>&#8722;</sup> signature was reported to define Th-GM [<xref ref-type="bibr" rid="CR56">56</xref>]. It is possible that Th-GM cooperate with Th1/17 cells or Th1 cells to exacerbate the development of inflammation.</p><p id="Par28">Th2 cells are also reported as one of the GM-CSF-producing cells [<xref ref-type="bibr" rid="CR57">57</xref>]. A positive correlation between GATA-3<sup>+</sup> cells and GM-CSF<sup>+</sup> cells in the nasal mucosa of allergic rhinitis patients is reported [<xref ref-type="bibr" rid="CR58">58</xref>]; however, the precise mechanism of GM-CSF production in Th2 cells has not been analyzed yet.</p></sec><sec id="Sec8"><title>GM-CSF in autoimmune disease</title><p id="Par29">Recent evidence revealed that GM-CSF played critical roles in the development of many autoimmune diseases. GM-CSF depletion or neutralization suppresses many autoimmune disease models, including EAE [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], arthritis [<xref ref-type="bibr" rid="CR59">59</xref>&#8211;<xref ref-type="bibr" rid="CR61">61</xref>], arthritis-related interstitial lung disease [<xref ref-type="bibr" rid="CR60">60</xref>], nephritis [<xref ref-type="bibr" rid="CR62">62</xref>], or psoriasis [<xref ref-type="bibr" rid="CR63">63</xref>]. On the other hand, GM-CSF administration is reported to improve the models of myasthenia gravis [<xref ref-type="bibr" rid="CR64">64</xref>], type 1 diabetes [<xref ref-type="bibr" rid="CR65">65</xref>], or colitis [<xref ref-type="bibr" rid="CR66">66</xref>].</p><sec id="Sec9"><title>GM-CSF in the CNS</title><p id="Par30">IL-17-producing Th17 cells have been reported as central mediators of CNS inflammation in both EAE and multiple sclerosis (MS) [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. However, recent studies reported that GM-CSF was essential for the encephalitogenicity of CD4 T cells in EAE and that IL-17 was dispensable for the development of EAE [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. The concentrations of GM-CSF and the number of GM-CSF-producing CD4 T cells in the cerebrospinal fluid were reported to be elevated in MS patients [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. GM-CSF deficiency or neutralization was reported to prevent the onset of EAE [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. In contrast, the administration of recombinant GM-CSF exacerbated EAE [<xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par31">GM-CSF induces the proliferation and activation of microglial cells which produce highly neurotoxic substances such as ROS, nitrogen species, and glutamate [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. GM-CSF-producing CD4 T cells also induce the polarization of neurotoxic M1-like phenotype of microglia and promote the production of pro-inflammatory cytokines such as IL-1&#946;, IL-6, and TNF&#945;, which also contribute to myelin sheath damage [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. GM-CSF is also required for the recruitment of peripheral myeloid cells that contribute to blood-brain barrier and blood-spinal cord barrier disruption and demyelization into the CNS [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. These resident and infiltrating antigen-presenting cells (APCs) re-stimulate T cells and lead to further APC activation [<xref ref-type="bibr" rid="CR76">76</xref>].</p></sec><sec id="Sec10"><title>GM-CSF in arthritis</title><p id="Par32">In the models of arthritis, IL-17 has been reported as a main pathogenic cytokine as in EAE [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. IL-17 deficiency ameliorated collagen-induced arthritis (CIA) but did not completely inhibit it [<xref ref-type="bibr" rid="CR78">78</xref>]. IL-17 inhibition was also reported to be an unsatisfactory method for the treatment of rheumatoid arthritis (RA) [<xref ref-type="bibr" rid="CR79">79</xref>]. These reports indicated the existence of the other critical factors in the development of arthritis.</p><p id="Par33">In RA patients, the concentration of GM-CSF in the synovial fluid and plasma was elevated [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>] and the administration of recombinant GM-CSF exacerbated the disease activity [<xref ref-type="bibr" rid="CR82">82</xref>]. Bone marrow adjacent to the RA joints contains an increased number of granulocyte-macrophage progenitors, colony-forming unit granulocyte-macrophages (CFU-GM), which can differentiate into granulocytes or macrophages with GM-CSF stimulation [<xref ref-type="bibr" rid="CR83">83</xref>] and also into osteoclasts with M-CSF and RANKL stimulation [<xref ref-type="bibr" rid="CR84">84</xref>]. The frequency of GM-CSF-producing T helper cells in synovial fluid cells was also significantly increased compared to peripheral blood mononuclear cells (PBMCs) and correlated with erythrocyte sedimentation rate (ESR) levels in juvenile idiopathic arthritis (JIA) [<xref ref-type="bibr" rid="CR85">85</xref>].</p><p id="Par34">In mouse models of arthritis, GM-CSF deficiency or neutralization prevented the development of arthritis [<xref ref-type="bibr" rid="CR59">59</xref>&#8211;<xref ref-type="bibr" rid="CR61">61</xref>] and reduced the concentrations of TNF and IL-1 in joints [<xref ref-type="bibr" rid="CR59">59</xref>]. Conversely, GM-CSF administration exacerbated arthritis [<xref ref-type="bibr" rid="CR86">86</xref>]. In arthritis of SKG mice, GM-CSF secreted by T cells upregulated the production of pro-inflammatory cytokines such as IL-6 or IL-1&#946; from macrophages [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. This in turn induced further differentiation and expansion of IL-17-producing and GM-CSF-producing CD4 T cells [<xref ref-type="bibr" rid="CR60">60</xref>] and exacerbated arthritis.</p><sec id="Sec11"><title>GM-CSF in arthritis-related interstitial lung disease</title><p id="Par35">SKG arthritis model develops chronic-progressive interstitial lung disease (ILD) which histologically resembles connective tissue disease-associated ILD (CTD-ILD) [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. This model was characterized with massive infiltration of Th17 cells, GM-CSF-producing CD4 T cells, and neutrophils with fibrosis in the lungs [<xref ref-type="bibr" rid="CR60">60</xref>]. The overexpression of GM-CSF was reported to induce severe neutrophil, eosinophil, and macrophage infiltration with fibrosis in the lungs [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. GM-CSF promotes macrophages to produce IL-6 and IL-1&#946; and enhances differentiation of IL-17A and/or GM-CSF-producing T cells and therefore infiltration of neutrophils into the lungs [<xref ref-type="bibr" rid="CR60">60</xref>]. Neutrophils were reported to produce ROS, MMPs, neutrophil elastase, or myeloperoxidase and cause parenchymal and stromal cell injury in the lungs [<xref ref-type="bibr" rid="CR91">91</xref>&#8211;<xref ref-type="bibr" rid="CR93">93</xref>]. GM-CSF also stimulates macrophages to release profibrotic cytokines and induces fibrosis by direct stimulation of airway smooth muscle cells [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. GM-CSF neutralization completely blocked the development of ILD in SKG mice but IL-17A neutralization did not, indicating that GM-CSF played a more critical role than IL-17A in this ILD [<xref ref-type="bibr" rid="CR60">60</xref>].</p><p id="Par36">The contribution of GM-CSF in human ILD has not been analyzed well yet. In patients with pulmonary fibrosis, the concentration of GM-CSF in the bronchoalveolar lavage fluid (BALF) was reported to be elevated [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. A recent report also reported that serum concentration of GM-CSF was associated with ILD in patients with RA [<xref ref-type="bibr" rid="CR97">97</xref>]. Further studies to clarify the contribution of GM-CSF in CTD-ILD are awaited.</p></sec></sec><sec id="Sec12"><title>GM-CSF in the intestine</title><p id="Par37">In the intestine, GM-CSF contributes to mucosal barrier function and resistance to bacterial translocation by promoting the recruitment and activation of myeloid cells. GM-CSF also promotes tissue repair via acceleration of epithelial cell proliferation and macrophages as effectors of wound healing [<xref ref-type="bibr" rid="CR98">98</xref>&#8211;<xref ref-type="bibr" rid="CR100">100</xref>].</p><p id="Par38">Recent studies suggested that mucosal innate immunodeficiency caused by a variety of genetic defects contributed the susceptibility of Crohn&#8217;s disease (CD) and increased the translocation of pathogens to the bowel tissue [<xref ref-type="bibr" rid="CR101">101</xref>]. Higher levels of GM-CSF secretion have been detected in mucosal lesions of inflammatory bowel disease (IBD) compared with normal mucosa [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>] and also in the colon lesions of dextran sodium (DSS)-induced colitis mice model [<xref ref-type="bibr" rid="CR104">104</xref>]. On the other hand, in CD, the increased levels of GM-CSF autoantibodies have been reported [<xref ref-type="bibr" rid="CR105">105</xref>]. The levels of GM-CSF autoantibodies correlated with the disease activity and inversely correlated with the neutrophil phagocytic activity in CD patients [<xref ref-type="bibr" rid="CR105">105</xref>]. GM-CSF-deficient mice were reported to be more susceptible to acute DSS-induced colitis [<xref ref-type="bibr" rid="CR106">106</xref>], and the severity of this colitis was largely prevented by GM-CSF administration [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. Conversely, GM-CSF neutralization was reported to ameliorate 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis [<xref ref-type="bibr" rid="CR108">108</xref>] and IL-23-driven colitis [<xref ref-type="bibr" rid="CR109">109</xref>]. The overexpression of GM-CSF in the stomach was reported to lead to autoimmune gastritis [<xref ref-type="bibr" rid="CR110">110</xref>]. These data indicated the possibilities that both relative shortage and excessive amount of GM-CSF could induce colitis. Further studies are also needed to clarify whether GM-CSF autoantibodies in CD patients are pathogenic or not pathogenic and produced just as a result of elevated GM-CSF.</p><p id="Par39">There are some trials of GM-CSF administration for the treatment of CD patients. Initial reports indicated a high rate of clinical response and remission with minimal adverse effects [<xref ref-type="bibr" rid="CR111">111</xref>&#8211;<xref ref-type="bibr" rid="CR113">113</xref>]. However, a recent large randomized trial reported that it is not effective for induction of clinical remission or improvement in active CD [<xref ref-type="bibr" rid="CR114">114</xref>]. The pathogenic mechanism of CD patients is considered to be heterogeneous. Therefore, GM-CSF administration might be effective only in some subgroups of patients.</p></sec></sec><sec id="Sec13"><title>GM-CSF target therapy</title><p id="Par40">There are several ongoing or completed clinical trials targeting GM-CSF or GM-CSF receptor (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Detailed information is available at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link>. Although GM-CSF inhibition showed rapid clinical response with no serious adverse reactions so far [<xref ref-type="bibr" rid="CR115">115</xref>&#8211;<xref ref-type="bibr" rid="CR117">117</xref>], there are some potential side effects which need to be monitored. The existence of GM-CSF autoantibodies or the mutations of GM-CSF receptor are reported to cause PAP [<xref ref-type="bibr" rid="CR6">6</xref>]. On the other hand, healthy individuals also have GM-CSF autoantibodies [<xref ref-type="bibr" rid="CR118">118</xref>], suggesting that the risk of PAP is increased only when GM-CSF autoantibody levels are increased above a critical threshold [<xref ref-type="bibr" rid="CR119">119</xref>]. In addition, GM-CSF inhibition might exacerbate the existing Crohn&#8217;s disease as mentioned above. An increased susceptibility to infections in GM-CSF-deficient mice [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR120">120</xref>] also indicates the risk of infection in GM-CSF target therapy.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical trials targeting GM-CSF</p></caption><table-wrap-foot><p>
<italic>Abbreviations</italic>: <italic>GM-CSFR</italic> GM-CSF receptor, <italic>RA</italic> rheumatoid arthritis, <italic>MS</italic> multiple sclerosis, <italic>MTX</italic> methotrexate</p></table-wrap-foot></table-wrap>
</p><sec id="Sec14"><title>Mavrilimumab</title><p id="Par41">Mavrilimumab is a human monoclonal antibody against GM-CSF receptor &#945;. In the first phase 1 study, 32 subjects with mild RA received single intravenous escalating doses of mavrilimumab and showed its safety and tolerability. Reductions of acute-phase reactants and disease activity score (DAS) 28 was also observed [<xref ref-type="bibr" rid="CR121">121</xref>].</p><p id="Par42">A phase 2a randomized, double-blind, placebo-controlled, ascending-dose study in subjects with moderate to severe active RA (EARTH study) reported significant efficacy with no serious adverse events [<xref ref-type="bibr" rid="CR117">117</xref>]. In this study, 239 patients with active RA despite methotrexate (MTX) treatment received subcutaneous mavrilimumab or placebo every other week for 12&#160;weeks on stable-background MTX therapy and 55.7&#160;% of all mavrilimumab-treated participants met the primary end point of achieving a &#8805;1.2 decrease from baseline in the DAS (DAS28-CRP) vs 34.7&#160;% of placebo-treated participants at week 12. All mavrilimumab-treated patients showed a response by week 2. The 100&#160;mg dose of mavrilimumab demonstrated a significant effect vs placebo on DAS28-CRP &lt;2.6, all categories of the American College of Rheumatology (ACR) criteria, and the Health Assessment Questionnaire Disability Index.</p><p id="Par43">In a subsequent phase 2b study (EARTH EXPLORER 1) [<xref ref-type="bibr" rid="CR122">122</xref>&#8211;<xref ref-type="bibr" rid="CR125">125</xref>], 326 patients with moderate to severe RA received an ascending dose of mavrilimumab or placebo every 2&#160;weeks plus MTX for 24&#160;weeks and showed an acceptable safety and tolerability. A statistically significant difference in DAS28-CRP was observed in all doses of mavrilimumab vs placebo at week 12, and a significantly higher ACR response rate of mavrilimumab-treated subjects than that of placebo was observed at week 24. Particularly, the 150&#160;mg dose showed a significant difference vs placebo for these parameters as early as week 1.</p><p id="Par44">A nonrandomized, open-label phase 2 study to evaluate the long-term safety and tolerability from day 1 through to approximately 5&#160;years is ongoing (NCT01712399) [<xref ref-type="bibr" rid="CR126">126</xref>]. This study enrolled RA patients who had completed the EARTH EXPLORER 1 and 2 studies or were rescued as inadequate responders at a predefined time point, and they received 100&#160;mg of mavrilimumab every other week. At week 74, mavrilimumab demonstrated sustained safety and efficacy with DAS28-CRP &lt;3.2 and &lt;2.5 rates of 57.3 and 38.5&#160;%, respectively, and 68&#160;% of patients showed no radiographic progression [<xref ref-type="bibr" rid="CR127">127</xref>].</p><p id="Par45">A randomized, double-blind, placebo-controlled phase 2 study (EARTH EXPLORER 2) to compare the safety and efficacy of mavrilimumab with those of golimumab, an anti-TNF antibody in 120 patients with moderate to severe RA who had an inadequate response to one or two anti-TNF agents, was completed [<xref ref-type="bibr" rid="CR128">128</xref>].</p></sec><sec id="Sec15"><title>MOR103</title><p id="Par46">MOR103, which is a fully human monoclonal antibody against GM-CSF, has shown preliminary evidence of safety and rapid efficacy (within 2&#160;weeks) in a randomized, double-blind, placebo-controlled, dose-escalating phase 1b/2a trial for patients with moderate RA (<italic>n</italic>&#8201;=&#8201;96) [<xref ref-type="bibr" rid="CR116">116</xref>]. Patients received four times of weekly intravenous MOR103 or placebo, and subjects receiving higher doses of MOR103 (1.0 and 1.5&#160;mg/kg) showed significant improvement in DAS28 scores and joint counts and significantly higher European League Against Rheumatism response rates than subjects receiving placebo.</p><p id="Par47">MOR103 was also tested in a randomized, double-blind, placebo-controlled phase 1b trial for patients with relapsing-remitting MS or secondary progressive MS. Patients received placebo or an escalating dose of MOR103 every 2&#160;weeks for 10&#160;weeks and showed acceptable tolerability of MOR103 [<xref ref-type="bibr" rid="CR115">115</xref>].</p></sec><sec id="Sec16"><title>Namilumab (MT203)</title><p id="Par48">Namilumab is a human monoclonal antibody against GM-CSF. In a randomized, double-blind, dose-escalating phase 1b study, mild to moderate RA patients received three times of every 2-week injection of namilumab and showed its safety and tolerability [<xref ref-type="bibr" rid="CR129">129</xref>]. The other trials testing namilumab is ongoing: a dose-finding phase 2 study of namilumab in combination with MTX in moderate to severe RA patients with inadequate response to MTX or one TNF inhibitor [<xref ref-type="bibr" rid="CR130">130</xref>] and a phase 2 trial to evaluate the efficacy and safety of the combination of the existing MTX and namilumab vs adalimumab, an anti-TNF antibody in patients with moderate to severe early RA inadequately responding to MTX [<xref ref-type="bibr" rid="CR131">131</xref>].</p><p id="Par49">It is also being tested in a randomized double-blind phase 2 trial for moderate to severe plaque psoriasis [<xref ref-type="bibr" rid="CR132">132</xref>].</p></sec><sec id="Sec17"><title>KB003</title><p id="Par50">KB003 is a humanized monoclonal antibody targeting GM-CSF. A randomized phase 2 study in RA patients showed safety and tolerability in 3&#160;months of repeated dosing [<xref ref-type="bibr" rid="CR133">133</xref>].</p></sec><sec id="Sec18"><title>MORAb-002</title><p id="Par51">MORAb-002 is a human monoclonal antibody against GM-CSF. A randomized, double-blind phase 1 trial in RA was completed recently [<xref ref-type="bibr" rid="CR134">134</xref>].</p></sec></sec><sec id="Sec19"><title>Conclusions</title><p id="Par52">Recent studies clarified the pivotal roles of GM-CSF in the development of many autoimmune diseases. Much attention has been focused on the inhibition of GM-CSF as an attractive approach for the treatment of these diseases. Further studies to clarify the molecular mechanism of GM-CSF production and precise role of GM-CSF in the development of autoimmune disease are awaited with interest.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>APC</term><def><p id="Par2">antigen-presenting cell</p></def></def-item><def-item><term>CIA</term><def><p id="Par3">collagen-induced arthritis</p></def></def-item><def-item><term>CTD-ILD</term><def><p id="Par4">connective tissue disease-associated interstitial lung disease</p></def></def-item><def-item><term>DAS</term><def><p id="Par5">disease activity score</p></def></def-item><def-item><term>DC</term><def><p id="Par6">dendritic cell</p></def></def-item><def-item><term>EAE</term><def><p id="Par7">experimental autoimmune encephalomyelitis</p></def></def-item><def-item><term>GM-CSF</term><def><p id="Par8">granulocyte-macrophage colony-stimulating factor</p></def></def-item><def-item><term>ILD</term><def><p id="Par9">interstitial lung disease</p></def></def-item><def-item><term>MS</term><def><p id="Par10">multiple sclerosis</p></def></def-item><def-item><term>MTX</term><def><p id="Par11">methotrexate</p></def></def-item><def-item><term>PAP</term><def><p id="Par12">pulmonary alveolar proteinosis</p></def></def-item><def-item><term>RA</term><def><p id="Par13">rheumatoid arthritis</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#8217; contributions</bold></p><p>AS drafted the manuscript. TU helped to draft the manuscript. TM gave the final approval of the version to be submitted and any revised version. All authors read and approved the final manuscript.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>AW</given-names></name><name><surname>Camakaris</surname><given-names>J</given-names></name><name><surname>Metcalf</surname><given-names>D</given-names></name></person-group><article-title>Purification and properties of colony-stimulating factor from mouse lung-conditioned medium</article-title><source>J Biol Chem</source><year>1977</year><volume>252</volume><fpage>1998</fpage><lpage>2003</lpage><?supplied-pmid 300377?><pub-id pub-id-type="pmid">300377</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>JA</given-names></name><name><surname>Achuthan</surname><given-names>A</given-names></name></person-group><article-title>Colony stimulating factors and myeloid cell biology in health and disease</article-title><source>Trends Immunol</source><year>2013</year><volume>34</volume><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.it.2012.08.006</pub-id><?supplied-pmid 23000011?><pub-id pub-id-type="pmid">23000011</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Behi</surname><given-names>M</given-names></name><name><surname>Ciric</surname><given-names>B</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Cullimore</surname><given-names>M</given-names></name><name><surname>Safavi</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>GX</given-names></name><name><surname>Dittel</surname><given-names>BN</given-names></name><name><surname>Rostami</surname><given-names>A</given-names></name></person-group><article-title>The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF</article-title><source>Nat Immunol</source><year>2011</year><volume>12</volume><fpage>568</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/ni.2031</pub-id><?supplied-pmid 21516111?><pub-id pub-id-type="pmid">21516111</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Codarri</surname><given-names>L</given-names></name><name><surname>Gy&#252;lv&#233;szi</surname><given-names>G</given-names></name><name><surname>Tosevski</surname><given-names>V</given-names></name><name><surname>Hesske</surname><given-names>L</given-names></name><name><surname>Fontana</surname><given-names>A</given-names></name><name><surname>Magnenat</surname><given-names>L</given-names></name><name><surname>Suter</surname><given-names>T</given-names></name><name><surname>Becher</surname><given-names>B</given-names></name></person-group><article-title>ROR&#947;t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation</article-title><source>Nat Immunol</source><year>2011</year><volume>12</volume><fpage>560</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1038/ni.2027</pub-id><?supplied-pmid 21516112?><pub-id pub-id-type="pmid">21516112</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>E</given-names></name><name><surname>Lieschke</surname><given-names>GJ</given-names></name><name><surname>Grail</surname><given-names>D</given-names></name><name><surname>Metcalf</surname><given-names>D</given-names></name><name><surname>Hodgson</surname><given-names>G</given-names></name><name><surname>Gall</surname><given-names>JA</given-names></name><name><surname>Maher</surname><given-names>DW</given-names></name><name><surname>Cebon</surname><given-names>J</given-names></name><name><surname>Sinickas</surname><given-names>V</given-names></name><name><surname>Dunn</surname><given-names>AR</given-names></name></person-group><article-title>Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology</article-title><source>Proc Natl Acad Sci U S A</source><year>1994</year><volume>91</volume><fpage>5592</fpage><lpage>5596</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.12.5592</pub-id><?supplied-pmid 8202532?><pub-id pub-id-type="pmid">8202532</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>B</given-names></name><name><surname>Trapnell</surname><given-names>BC</given-names></name></person-group><article-title>The molecular basis of pulmonary alveolar proteinosis</article-title><source>Clin Immunol</source><year>2010</year><volume>135</volume><fpage>223</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2010.02.017</pub-id><?supplied-pmid 20338813?><pub-id pub-id-type="pmid">20338813</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleetwood</surname><given-names>AJ</given-names></name><name><surname>Lawrence</surname><given-names>T</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name><name><surname>Cook</surname><given-names>AD</given-names></name></person-group><article-title>Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation</article-title><source>J Immunol</source><year>2007</year><volume>178</volume><fpage>5245</fpage><lpage>5252</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.8.5245</pub-id><?supplied-pmid 17404308?><pub-id pub-id-type="pmid">17404308</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrissey</surname><given-names>PJ</given-names></name><name><surname>Bressler</surname><given-names>L</given-names></name><name><surname>Park</surname><given-names>LS</given-names></name><name><surname>Alpert</surname><given-names>A</given-names></name><name><surname>Gillis</surname><given-names>S</given-names></name></person-group><article-title>Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells</article-title><source>J Immunol</source><year>1987</year><volume>139</volume><fpage>1113</fpage><lpage>1119</lpage><?supplied-pmid 3038997?><pub-id pub-id-type="pmid">3038997</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berclaz</surname><given-names>PY</given-names></name><name><surname>Zsengell&#233;r</surname><given-names>Z</given-names></name><name><surname>Shibata</surname><given-names>Y</given-names></name><name><surname>Otake</surname><given-names>K</given-names></name><name><surname>Strasbaugh</surname><given-names>S</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name><name><surname>Trapnell</surname><given-names>BC</given-names></name></person-group><article-title>Endocytic internalization of adenovirus, nonspecific phagocytosis, and cytoskeletal organization are coordinately regulated in alveolar macrophages by GM-CSF and PU.1</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>6332</fpage><lpage>6342</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.11.6332</pub-id><?supplied-pmid 12444140?><pub-id pub-id-type="pmid">12444140</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berclaz</surname><given-names>PY</given-names></name><name><surname>Shibata</surname><given-names>Y</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name><name><surname>Trapnell</surname><given-names>BC</given-names></name></person-group><article-title>GM-CSF, via PU.1, regulates alveolar macrophage Fcgamma R-mediated phagocytosis and the IL-18/IFN-gamma -mediated molecular connection between innate and adaptive immunity in the lung</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>4193</fpage><lpage>4200</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-04-1102</pub-id><?supplied-pmid 12393686?><pub-id pub-id-type="pmid">12393686</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>HL</given-names></name><name><surname>Bancroft</surname><given-names>GJ</given-names></name></person-group><article-title>Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans</article-title><source>Eur J Immunol</source><year>1992</year><volume>22</volume><fpage>1447</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1002/eji.1830220617</pub-id><?supplied-pmid 1601035?><pub-id pub-id-type="pmid">1601035</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakagami</surname><given-names>T</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Carey</surname><given-names>BC</given-names></name><name><surname>Wood</surname><given-names>RE</given-names></name><name><surname>Wert</surname><given-names>SE</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name><name><surname>Trapnell</surname><given-names>BC</given-names></name><name><surname>Luisetti</surname><given-names>M</given-names></name></person-group><article-title>Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>2679</fpage><lpage>2681</lpage><pub-id pub-id-type="doi">10.1056/NEJMc0904077</pub-id><?supplied-pmid 20042763?><pub-id pub-id-type="pmid">20042763</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Cambronero</surname><given-names>J</given-names></name><name><surname>Horn</surname><given-names>J</given-names></name><name><surname>Paul</surname><given-names>CC</given-names></name><name><surname>Baumann</surname><given-names>MA</given-names></name></person-group><article-title>Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>6846</fpage><lpage>6855</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.12.6846</pub-id><?supplied-pmid 14662891?><pub-id pub-id-type="pmid">14662891</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verreck</surname><given-names>FA</given-names></name><name><surname>de Boer</surname><given-names>T</given-names></name><name><surname>Langenberg</surname><given-names>DM</given-names></name><name><surname>Hoeve</surname><given-names>MA</given-names></name><name><surname>Kramer</surname><given-names>M</given-names></name><name><surname>Vaisberg</surname><given-names>E</given-names></name><name><surname>Kastelein</surname><given-names>R</given-names></name><name><surname>Kolk</surname><given-names>A</given-names></name><name><surname>de Waal-Malefyt</surname><given-names>R</given-names></name><name><surname>Ottenhoff</surname><given-names>TH</given-names></name></person-group><article-title>Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>4560</fpage><lpage>4565</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400983101</pub-id><?supplied-pmid 15070757?><pub-id pub-id-type="pmid">15070757</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krausgruber</surname><given-names>T</given-names></name><name><surname>Blazek</surname><given-names>K</given-names></name><name><surname>Smallie</surname><given-names>T</given-names></name><name><surname>Alzabin</surname><given-names>S</given-names></name><name><surname>Lockstone</surname><given-names>H</given-names></name><name><surname>Sahgal</surname><given-names>N</given-names></name><name><surname>Hussell</surname><given-names>T</given-names></name><name><surname>Feldmann</surname><given-names>M</given-names></name><name><surname>Udalova</surname><given-names>IA</given-names></name></person-group><article-title>IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses</article-title><source>Nat Immunol</source><year>2011</year><volume>12</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1038/ni.1990</pub-id><?supplied-pmid 21240265?><pub-id pub-id-type="pmid">21240265</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cates</surname><given-names>EC</given-names></name><name><surname>Fattouh</surname><given-names>R</given-names></name><name><surname>Wattie</surname><given-names>J</given-names></name><name><surname>Inman</surname><given-names>MD</given-names></name><name><surname>Goncharova</surname><given-names>S</given-names></name><name><surname>Coyle</surname><given-names>AJ</given-names></name><name><surname>Gutierrez-Ramos</surname><given-names>JC</given-names></name><name><surname>Jordana</surname><given-names>M</given-names></name></person-group><article-title>Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>6384</fpage><lpage>6392</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.10.6384</pub-id><?supplied-pmid 15528378?><pub-id pub-id-type="pmid">15528378</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willart</surname><given-names>MA</given-names></name><name><surname>Deswarte</surname><given-names>K</given-names></name><name><surname>Pouliot</surname><given-names>P</given-names></name><name><surname>Braun</surname><given-names>H</given-names></name><name><surname>Beyaert</surname><given-names>R</given-names></name><name><surname>Lambrecht</surname><given-names>BN</given-names></name><name><surname>Hammad</surname><given-names>H</given-names></name></person-group><article-title>Interleukin-1&#945; controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33</article-title><source>J Exp Med</source><year>2012</year><volume>209</volume><fpage>1505</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1084/jem.20112691</pub-id><?supplied-pmid 22802353?><pub-id pub-id-type="pmid">22802353</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogunovic</surname><given-names>M</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Helft</surname><given-names>J</given-names></name><name><surname>Shang</surname><given-names>L</given-names></name><name><surname>Hashimoto</surname><given-names>D</given-names></name><name><surname>Greter</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Jakubzick</surname><given-names>C</given-names></name><name><surname>Ingersoll</surname><given-names>MA</given-names></name><name><surname>Leboeuf</surname><given-names>M</given-names></name><etal/></person-group><article-title>Origin of the lamina propria dendritic cell network</article-title><source>Immunity</source><year>2009</year><volume>31</volume><fpage>513</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.08.010</pub-id><?supplied-pmid 19733489?><pub-id pub-id-type="pmid">19733489</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Lew</surname><given-names>AM</given-names></name></person-group><article-title>The regulation of the development and function of dendritic cell subsets by GM-CSF: more than a hematopoietic growth factor</article-title><source>Mol Immunol</source><year>2012</year><volume>52</volume><fpage>30</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2012.04.009</pub-id><?supplied-pmid 22580403?><pub-id pub-id-type="pmid">22580403</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esashi</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Perng</surname><given-names>O</given-names></name><name><surname>Qin</surname><given-names>XF</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name><name><surname>Watowich</surname><given-names>SS</given-names></name></person-group><article-title>The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8</article-title><source>Immunity</source><year>2008</year><volume>28</volume><fpage>509</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.02.013</pub-id><?supplied-pmid 18342552?><pub-id pub-id-type="pmid">18342552</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caux</surname><given-names>C</given-names></name><name><surname>Vanbervliet</surname><given-names>B</given-names></name><name><surname>Massacrier</surname><given-names>C</given-names></name><name><surname>Dezutter-Dambuyant</surname><given-names>C</given-names></name><name><surname>de Saint-Vis</surname><given-names>B</given-names></name><name><surname>Jacquet</surname><given-names>C</given-names></name><name><surname>Yoneda</surname><given-names>K</given-names></name><name><surname>Imamura</surname><given-names>S</given-names></name><name><surname>Schmitt</surname><given-names>D</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name></person-group><article-title>CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+ TNF alpha</article-title><source>J Exp Med</source><year>1996</year><volume>184</volume><fpage>695</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1084/jem.184.2.695</pub-id><?supplied-pmid 8760823?><pub-id pub-id-type="pmid">8760823</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>Y</given-names></name><name><surname>Carrington</surname><given-names>EM</given-names></name><name><surname>van Nieuwenhuijze</surname><given-names>A</given-names></name><name><surname>Bedoui</surname><given-names>S</given-names></name><name><surname>Seah</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Mintern</surname><given-names>JD</given-names></name><name><surname>Villadangos</surname><given-names>JA</given-names></name><name><surname>Wicks</surname><given-names>IP</given-names></name><name><surname>Lew</surname><given-names>AM</given-names></name></person-group><article-title>GM-CSF increases cross-presentation and CD103 expression by mouse CD8<sup>+</sup> spleen dendritic cells</article-title><source>Eur J Immunol</source><year>2011</year><volume>41</volume><fpage>2585</fpage><lpage>2595</lpage><pub-id pub-id-type="doi">10.1002/eji.201141540</pub-id><?supplied-pmid 21660938?><pub-id pub-id-type="pmid">21660938</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>IK</given-names></name><name><surname>van Nieuwenhuijze</surname><given-names>A</given-names></name><name><surname>Segura</surname><given-names>E</given-names></name><name><surname>O'Donnell</surname><given-names>K</given-names></name><name><surname>Coghill</surname><given-names>E</given-names></name><name><surname>Hommel</surname><given-names>M</given-names></name><name><surname>Gerondakis</surname><given-names>S</given-names></name><name><surname>Villadangos</surname><given-names>JA</given-names></name><name><surname>Wicks</surname><given-names>IP</given-names></name></person-group><article-title>Differentiation of inflammatory dendritic cells is mediated by NF-&#954;B1-dependent GM-CSF production in CD4 T cells</article-title><source>J Immunol</source><year>2011</year><volume>186</volume><fpage>5468</fpage><lpage>5477</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1002923</pub-id><?supplied-pmid 21421852?><pub-id pub-id-type="pmid">21421852</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greter</surname><given-names>M</given-names></name><name><surname>Helft</surname><given-names>J</given-names></name><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Hashimoto</surname><given-names>D</given-names></name><name><surname>Mortha</surname><given-names>A</given-names></name><name><surname>Agudo-Cantero</surname><given-names>J</given-names></name><name><surname>Bogunovic</surname><given-names>M</given-names></name><name><surname>Gautier</surname><given-names>EL</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Leboeuf</surname><given-names>M</given-names></name><etal/></person-group><article-title>GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells</article-title><source>Immunity</source><year>2012</year><volume>36</volume><fpage>1031</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.027</pub-id><?supplied-pmid 22749353?><pub-id pub-id-type="pmid">22749353</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Beck</surname><given-names>DC</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Berclaz</surname><given-names>PY</given-names></name><name><surname>Abe</surname><given-names>S</given-names></name><name><surname>Staudt</surname><given-names>MK</given-names></name><name><surname>Carey</surname><given-names>BC</given-names></name><name><surname>Filippi</surname><given-names>MD</given-names></name><name><surname>Wert</surname><given-names>SE</given-names></name><name><surname>Denson</surname><given-names>LA</given-names></name><etal/></person-group><article-title>GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>567</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa062505</pub-id><?supplied-pmid 17287477?><pub-id pub-id-type="pmid">17287477</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamopoulos</surname><given-names>IE</given-names></name><name><surname>Mellins</surname><given-names>ED</given-names></name></person-group><article-title>Alternative pathways of osteoclastogenesis in inflammatory arthritis</article-title><source>Nat Rev Rheumatol</source><year>2015</year><volume>11</volume><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2014.198</pub-id><?supplied-pmid 25422000?><pub-id pub-id-type="pmid">25422000</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiasa</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Nakano</surname><given-names>A</given-names></name><name><surname>Oda</surname><given-names>A</given-names></name><name><surname>Amou</surname><given-names>H</given-names></name><name><surname>Kido</surname><given-names>S</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Kagawa</surname><given-names>K</given-names></name><name><surname>Yata</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE)</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>4517</fpage><lpage>4526</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-04-215020</pub-id><?supplied-pmid 19762488?><pub-id pub-id-type="pmid">19762488</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname><given-names>K</given-names></name><name><surname>Kuroda</surname><given-names>S</given-names></name><name><surname>Yoshikawa</surname><given-names>H</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name></person-group><article-title>Inflammatory osteoclastogenesis can be induced by GM-CSF and activated under TNF immunity</article-title><source>Biochem Biophys Res Commun</source><year>2008</year><volume>367</volume><fpage>881</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.01.023</pub-id><?supplied-pmid 18201554?><pub-id pub-id-type="pmid">18201554</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivollier</surname><given-names>A</given-names></name><name><surname>Mazzorana</surname><given-names>M</given-names></name><name><surname>Tebib</surname><given-names>J</given-names></name><name><surname>Piperno</surname><given-names>M</given-names></name><name><surname>Aitsiselmi</surname><given-names>T</given-names></name><name><surname>Rabourdin-Combe</surname><given-names>C</given-names></name><name><surname>Jurdic</surname><given-names>P</given-names></name><name><surname>Servet-Delprat</surname><given-names>C</given-names></name></person-group><article-title>Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>4029</fpage><lpage>4037</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-01-0041</pub-id><?supplied-pmid 15308576?><pub-id pub-id-type="pmid">15308576</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Yeon</surname><given-names>JT</given-names></name><name><surname>Choi</surname><given-names>SW</given-names></name><name><surname>Chun</surname><given-names>CH</given-names></name><name><surname>Kwak</surname><given-names>HB</given-names></name><name><surname>Oh</surname><given-names>J</given-names></name></person-group><article-title>GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway</article-title><source>J Immunol</source><year>2009</year><volume>183</volume><fpage>3390</fpage><lpage>3399</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0804314</pub-id><?supplied-pmid 19641137?><pub-id pub-id-type="pmid">19641137</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>PJ</given-names></name><name><surname>Chudnovskiy</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>CS</given-names></name><name><surname>Weber</surname><given-names>GF</given-names></name><name><surname>Etzrodt</surname><given-names>M</given-names></name><name><surname>Hilgendorf</surname><given-names>I</given-names></name><name><surname>Tiglao</surname><given-names>E</given-names></name><name><surname>Figueiredo</surname><given-names>JL</given-names></name><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Theurl</surname><given-names>I</given-names></name><etal/></person-group><article-title>Innate response activator B cells protect against microbial sepsis</article-title><source>Science</source><year>2012</year><volume>335</volume><fpage>597</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1126/science.1215173</pub-id><?supplied-pmid 22245738?><pub-id pub-id-type="pmid">22245738</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>GF</given-names></name><name><surname>Chousterman</surname><given-names>BG</given-names></name><name><surname>Hilgendorf</surname><given-names>I</given-names></name><name><surname>Robbins</surname><given-names>CS</given-names></name><name><surname>Theurl</surname><given-names>I</given-names></name><name><surname>Gerhardt</surname><given-names>LM</given-names></name><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Quach</surname><given-names>TD</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis</article-title><source>J Exp Med</source><year>2014</year><volume>211</volume><fpage>1243</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1084/jem.20131471</pub-id><?supplied-pmid 24821911?><pub-id pub-id-type="pmid">24821911</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweizerhof</surname><given-names>M</given-names></name><name><surname>St&#246;sser</surname><given-names>S</given-names></name><name><surname>Kurejova</surname><given-names>M</given-names></name><name><surname>Njoo</surname><given-names>C</given-names></name><name><surname>Gangadharan</surname><given-names>V</given-names></name><name><surname>Agarwal</surname><given-names>N</given-names></name><name><surname>Schmelz</surname><given-names>M</given-names></name><name><surname>Bali</surname><given-names>KK</given-names></name><name><surname>Michalski</surname><given-names>CW</given-names></name><name><surname>Brugger</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain</article-title><source>Nat Med</source><year>2009</year><volume>15</volume><fpage>802</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1038/nm.1976</pub-id><?supplied-pmid 19525966?><pub-id pub-id-type="pmid">19525966</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>AD</given-names></name><name><surname>Pobjoy</surname><given-names>J</given-names></name><name><surname>Sarros</surname><given-names>S</given-names></name><name><surname>Steidl</surname><given-names>S</given-names></name><name><surname>D&#252;rr</surname><given-names>M</given-names></name><name><surname>Lacey</surname><given-names>DC</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name></person-group><article-title>Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-201703</pub-id><?supplied-pmid 22833372?><pub-id pub-id-type="pmid">22833372</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>AD</given-names></name><name><surname>Pobjoy</surname><given-names>J</given-names></name><name><surname>Steidl</surname><given-names>S</given-names></name><name><surname>D&#252;rr</surname><given-names>M</given-names></name><name><surname>Braine</surname><given-names>EL</given-names></name><name><surname>Turner</surname><given-names>AL</given-names></name><name><surname>Lacey</surname><given-names>DC</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name></person-group><article-title>Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development</article-title><source>Arthritis Res Ther</source><year>2012</year><volume>14</volume><fpage>R199</fpage><pub-id pub-id-type="doi">10.1186/ar4037</pub-id><?supplied-pmid 22995428?><pub-id pub-id-type="pmid">22995428</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Moczygemba</surname><given-names>M</given-names></name><name><surname>Huston</surname><given-names>DP</given-names></name></person-group><article-title>Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF</article-title><source>J Allergy Clin Immunol</source><year>2003</year><volume>112</volume><fpage>653</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2003.08.015</pub-id><?supplied-pmid 14564341?><pub-id pub-id-type="pmid">14564341</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hercus</surname><given-names>TR</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Guthridge</surname><given-names>MA</given-names></name><name><surname>Ekert</surname><given-names>PG</given-names></name><name><surname>King-Scott</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>MW</given-names></name><name><surname>Lopez</surname><given-names>AF</given-names></name></person-group><article-title>The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>1289</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-12-164004</pub-id><?supplied-pmid 19436055?><pub-id pub-id-type="pmid">19436055</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broughton</surname><given-names>SE</given-names></name><name><surname>Nero</surname><given-names>TL</given-names></name><name><surname>Dhagat</surname><given-names>U</given-names></name><name><surname>Kan</surname><given-names>WL</given-names></name><name><surname>Hercus</surname><given-names>TR</given-names></name><name><surname>Tvorogov</surname><given-names>D</given-names></name><name><surname>Lopez</surname><given-names>AF</given-names></name><name><surname>Parker</surname><given-names>MW</given-names></name></person-group><article-title>The &#946;c receptor family&#8212;structural insights and their functional implications</article-title><source>Cytokine</source><year>2015</year><volume>74</volume><fpage>247</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2015.02.005</pub-id><?supplied-pmid 25982846?><pub-id pub-id-type="pmid">25982846</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosas</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>PR</given-names></name></person-group><article-title>Characterisation of the expression and function of the GM-CSF receptor alpha-chain in mice</article-title><source>Eur J Immunol</source><year>2007</year><volume>37</volume><fpage>2518</fpage><lpage>2528</lpage><pub-id pub-id-type="doi">10.1002/eji.200636892</pub-id><?supplied-pmid 17694571?><pub-id pub-id-type="pmid">17694571</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tumor-derived GM-CSF promotes inflammatory colon carcinogenesis via stimulating epithelial release of VEGF</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><fpage>716</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1459</pub-id><?supplied-pmid 24366884?><pub-id pub-id-type="pmid">24366884</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colotta</surname><given-names>F</given-names></name><name><surname>Bussolino</surname><given-names>F</given-names></name><name><surname>Polentarutti</surname><given-names>N</given-names></name><name><surname>Guglielmetti</surname><given-names>A</given-names></name><name><surname>Sironi</surname><given-names>M</given-names></name><name><surname>Bocchietto</surname><given-names>E</given-names></name><name><surname>De Rossi</surname><given-names>M</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Differential expression of the common beta and specific alpha chains of the receptors for GM-CSF, IL-3, and IL-5 in endothelial cells</article-title><source>Exp Cell Res</source><year>1993</year><volume>206</volume><fpage>311</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1006/excr.1993.1151</pub-id><?supplied-pmid 7684696?><pub-id pub-id-type="pmid">7684696</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prevost</surname><given-names>JM</given-names></name><name><surname>Pelley</surname><given-names>JL</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>D'Egidio</surname><given-names>GE</given-names></name><name><surname>Beaudry</surname><given-names>PP</given-names></name><name><surname>Pihl</surname><given-names>C</given-names></name><name><surname>Neely</surname><given-names>GG</given-names></name><name><surname>Claret</surname><given-names>E</given-names></name><name><surname>Wijdenes</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>CB</given-names></name></person-group><article-title>Granulocyte-macrophage colony-stimulating factor (GM-CSF) and inflammatory stimuli up-regulate secretion of the soluble GM-CSF receptor in human monocytes: evidence for ectodomain shedding of the cell surface GM-CSF receptor alpha subunit</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>5679</fpage><lpage>5688</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.10.5679</pub-id><?supplied-pmid 12421947?><pub-id pub-id-type="pmid">12421947</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>CB</given-names></name><name><surname>Beaudry</surname><given-names>P</given-names></name><name><surname>Laing</surname><given-names>TD</given-names></name><name><surname>Shoemaker</surname><given-names>S</given-names></name><name><surname>Kaushansky</surname><given-names>K</given-names></name></person-group><article-title>In vitro characterization of the human recombinant soluble granulocyte-macrophage colony-stimulating factor receptor</article-title><source>Blood</source><year>1995</year><volume>85</volume><fpage>1488</fpage><lpage>1495</lpage><?supplied-pmid 7888670?><pub-id pub-id-type="pmid">7888670</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiomi</surname><given-names>A</given-names></name><name><surname>Usui</surname><given-names>T</given-names></name></person-group><article-title>Pivotal roles of GM-CSF in autoimmunity and inflammation</article-title><source>Mediators Inflamm</source><year>2015</year><volume>2015</volume><fpage>568543</fpage><pub-id pub-id-type="doi">10.1155/2015/568543</pub-id><?supplied-pmid 25838639?><pub-id pub-id-type="pmid">25838639</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>JA</given-names></name></person-group><article-title>GM-CSF in inflammation and autoimmunity</article-title><source>Trends Immunol</source><year>2002</year><volume>23</volume><fpage>403</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/S1471-4906(02)02260-3</pub-id><?supplied-pmid 12133803?><pub-id pub-id-type="pmid">12133803</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quill</surname><given-names>H</given-names></name><name><surname>Gaur</surname><given-names>A</given-names></name><name><surname>Phipps</surname><given-names>RP</given-names></name></person-group><article-title>Prostaglandin E2-dependent induction of granulocyte-macrophage colony-stimulating factor secretion by cloned murine helper T cells</article-title><source>J Immunol</source><year>1989</year><volume>142</volume><fpage>813</fpage><lpage>818</lpage><?supplied-pmid 2521509?><pub-id pub-id-type="pmid">2521509</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinewietfeld</surname><given-names>M</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name></person-group><article-title>The plasticity of human Treg and Th17 cells and its role in autoimmunity</article-title><source>Semin Immunol</source><year>2013</year><volume>25</volume><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2013.10.009</pub-id><?supplied-pmid 24211039?><pub-id pub-id-type="pmid">24211039</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghoreschi</surname><given-names>K</given-names></name><name><surname>Laurence</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>XP</given-names></name><name><surname>Tato</surname><given-names>CM</given-names></name><name><surname>McGeachy</surname><given-names>MJ</given-names></name><name><surname>Konkel</surname><given-names>JE</given-names></name><name><surname>Ramos</surname><given-names>HL</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Davidson</surname><given-names>TS</given-names></name><name><surname>Bouladoux</surname><given-names>N</given-names></name><etal/></person-group><article-title>Generation of pathogenic T(H)17 cells in the absence of TGF-&#946; signalling</article-title><source>Nature</source><year>2010</year><volume>467</volume><fpage>967</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1038/nature09447</pub-id><?supplied-pmid 20962846?><pub-id pub-id-type="pmid">20962846</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group><article-title>The many faces of Th17 cells</article-title><source>Curr Opin Immunol</source><year>2011</year><volume>23</volume><fpage>702</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2011.08.007</pub-id><?supplied-pmid 21899997?><pub-id pub-id-type="pmid">21899997</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duhen</surname><given-names>T</given-names></name><name><surname>Campbell</surname><given-names>DJ</given-names></name></person-group><article-title>IL-1&#946; promotes the differentiation of polyfunctional human CCR6+ CXCR3+ Th1/17 cells that are specific for pathogenic and commensal microbes</article-title><source>J Immunol</source><year>2014</year><volume>193</volume><fpage>120</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302734</pub-id><?supplied-pmid 24890729?><pub-id pub-id-type="pmid">24890729</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maggi</surname><given-names>L</given-names></name><name><surname>Santarlasci</surname><given-names>V</given-names></name><name><surname>Capone</surname><given-names>M</given-names></name><name><surname>Peired</surname><given-names>A</given-names></name><name><surname>Frosali</surname><given-names>F</given-names></name><name><surname>Crome</surname><given-names>SQ</given-names></name><name><surname>Querci</surname><given-names>V</given-names></name><name><surname>Fambrini</surname><given-names>M</given-names></name><name><surname>Liotta</surname><given-names>F</given-names></name><name><surname>Levings</surname><given-names>MK</given-names></name><etal/></person-group><article-title>CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC</article-title><source>Eur J Immunol</source><year>2010</year><volume>40</volume><fpage>2174</fpage><lpage>2181</lpage><pub-id pub-id-type="doi">10.1002/eji.200940257</pub-id><?supplied-pmid 20486123?><pub-id pub-id-type="pmid">20486123</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kara</surname><given-names>EE</given-names></name><name><surname>McKenzie</surname><given-names>DR</given-names></name><name><surname>Bastow</surname><given-names>CR</given-names></name><name><surname>Gregor</surname><given-names>CE</given-names></name><name><surname>Fenix</surname><given-names>KA</given-names></name><name><surname>Ogunniyi</surname><given-names>AD</given-names></name><name><surname>Paton</surname><given-names>JC</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Pombal</surname><given-names>DR</given-names></name><name><surname>Seillet</surname><given-names>C</given-names></name><etal/></person-group><article-title>CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>8644</fpage><pub-id pub-id-type="doi">10.1038/ncomms9644</pub-id><?supplied-pmid 26511769?><pub-id pub-id-type="pmid">26511769</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Malley</surname><given-names>JT</given-names></name><name><surname>Eri</surname><given-names>RD</given-names></name><name><surname>Stritesky</surname><given-names>GL</given-names></name><name><surname>Mathur</surname><given-names>AN</given-names></name><name><surname>Chang</surname><given-names>HC</given-names></name><name><surname>Hogenesch</surname><given-names>H</given-names></name><name><surname>Srinivasan</surname><given-names>M</given-names></name><name><surname>Kaplan</surname><given-names>MH</given-names></name></person-group><article-title>STAT4 isoforms differentially regulate Th1 cytokine production and the severity of inflammatory bowel disease</article-title><source>J Immunol</source><year>2008</year><volume>181</volume><fpage>5062</fpage><lpage>5070</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.7.5062</pub-id><?supplied-pmid 18802110?><pub-id pub-id-type="pmid">18802110</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolarz</surname><given-names>G</given-names></name><name><surname>Scherak</surname><given-names>O</given-names></name><name><surname>Popp</surname><given-names>W</given-names></name><name><surname>Ritschka</surname><given-names>L</given-names></name><name><surname>Thumb</surname><given-names>N</given-names></name><name><surname>Wottawa</surname><given-names>A</given-names></name><name><surname>Zwick</surname><given-names>H</given-names></name></person-group><article-title>Bronchoalveolar lavage in rheumatoid arthritis</article-title><source>Br J Rheumatol</source><year>1993</year><volume>32</volume><fpage>556</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/32.7.556</pub-id><?supplied-pmid 8339125?><pub-id pub-id-type="pmid">8339125</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Low</surname><given-names>PY</given-names></name><name><surname>Kemeny</surname><given-names>DM</given-names></name><name><surname>Tan</surname><given-names>P</given-names></name><name><surname>Moh</surname><given-names>A</given-names></name><name><surname>Kaplan</surname><given-names>MH</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>XY</given-names></name></person-group><article-title>STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation</article-title><source>Cell Res</source><year>2014</year><volume>24</volume><fpage>1387</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1038/cr.2014.154</pub-id><?supplied-pmid 25412660?><pub-id pub-id-type="pmid">25412660</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noster</surname><given-names>R</given-names></name><name><surname>Riedel</surname><given-names>R</given-names></name><name><surname>Mashreghi</surname><given-names>MF</given-names></name><name><surname>Radbruch</surname><given-names>H</given-names></name><name><surname>Harms</surname><given-names>L</given-names></name><name><surname>Haftmann</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>HD</given-names></name><name><surname>Radbruch</surname><given-names>A</given-names></name><name><surname>Zielinski</surname><given-names>CE</given-names></name></person-group><article-title>IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><fpage>241ra280</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3008706</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cousins</surname><given-names>DJ</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Staynov</surname><given-names>DZ</given-names></name></person-group><article-title>Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression of Th2 cytokines</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>2498</fpage><lpage>2506</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.5.2498</pub-id><?supplied-pmid 12193719?><pub-id pub-id-type="pmid">12193719</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Christodoulopoulos</surname><given-names>P</given-names></name><name><surname>Cameron</surname><given-names>L</given-names></name><name><surname>Wright</surname><given-names>E</given-names></name><name><surname>Lavigne</surname><given-names>F</given-names></name><name><surname>Toda</surname><given-names>M</given-names></name><name><surname>Muro</surname><given-names>S</given-names></name><name><surname>Ray</surname><given-names>A</given-names></name><name><surname>Eidelman</surname><given-names>DH</given-names></name><name><surname>Minshall</surname><given-names>E</given-names></name><name><surname>Hamid</surname><given-names>Q</given-names></name></person-group><article-title>Upregulation of the transcription factor GATA-3 in upper airway mucosa after in vivo and in vitro allergen challenge</article-title><source>J Allergy Clin Immunol</source><year>2000</year><volume>105</volume><fpage>1146</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1067/mai.2000.107045</pub-id><?supplied-pmid 10856149?><pub-id pub-id-type="pmid">10856149</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>AD</given-names></name><name><surname>Braine</surname><given-names>EL</given-names></name><name><surname>Campbell</surname><given-names>IK</given-names></name><name><surname>Rich</surname><given-names>MJ</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name></person-group><article-title>Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease</article-title><source>Arthritis Res</source><year>2001</year><volume>3</volume><fpage>293</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1186/ar318</pub-id><?supplied-pmid 11549370?><pub-id pub-id-type="pmid">11549370</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiomi</surname><given-names>A</given-names></name><name><surname>Usui</surname><given-names>T</given-names></name><name><surname>Ishikawa</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Mimori</surname><given-names>T</given-names></name></person-group><article-title>GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice</article-title><source>J Immunol</source><year>2014</year><volume>193</volume><fpage>849</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1303255</pub-id><?supplied-pmid 24951817?><pub-id pub-id-type="pmid">24951817</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>IK</given-names></name><name><surname>Rich</surname><given-names>MJ</given-names></name><name><surname>Bischof</surname><given-names>RJ</given-names></name><name><surname>Dunn</surname><given-names>AR</given-names></name><name><surname>Grail</surname><given-names>D</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name></person-group><article-title>Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>3639</fpage><lpage>3644</lpage><?supplied-pmid 9759887?><pub-id pub-id-type="pmid">9759887</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitching</surname><given-names>AR</given-names></name><name><surname>Ru Huang</surname><given-names>X</given-names></name><name><surname>Turner</surname><given-names>AL</given-names></name><name><surname>Tipping</surname><given-names>PG</given-names></name><name><surname>Dunn</surname><given-names>AR</given-names></name><name><surname>Holdsworth</surname><given-names>SR</given-names></name></person-group><article-title>The requirement for granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in leukocyte-mediated immune glomerular injury</article-title><source>J Am Soc Nephrol</source><year>2002</year><volume>13</volume><fpage>350</fpage><lpage>358</lpage><?supplied-pmid 11805162?><pub-id pub-id-type="pmid">11805162</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#246;n</surname><given-names>M</given-names></name><name><surname>Denzer</surname><given-names>D</given-names></name><name><surname>Kubitza</surname><given-names>RC</given-names></name><name><surname>Ruzicka</surname><given-names>T</given-names></name><name><surname>Sch&#246;n</surname><given-names>MP</given-names></name></person-group><article-title>Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice</article-title><source>J Invest Dermatol</source><year>2000</year><volume>114</volume><fpage>976</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1747.2000.00953.x</pub-id><?supplied-pmid 10771480?><pub-id pub-id-type="pmid">10771480</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>JR</given-names></name><name><surname>Muthusamy</surname><given-names>T</given-names></name><name><surname>Prabhakar</surname><given-names>BS</given-names></name><name><surname>Meriggioli</surname><given-names>MN</given-names></name></person-group><article-title>GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis</article-title><source>J Neuroimmunol</source><year>2011</year><volume>240&#8211;241</volume><fpage>65</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2011.10.010</pub-id><?supplied-pmid 22099723?><pub-id pub-id-type="pmid">22099723</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaudreau</surname><given-names>S</given-names></name><name><surname>Guindi</surname><given-names>C</given-names></name><name><surname>M&#233;nard</surname><given-names>M</given-names></name><name><surname>Besin</surname><given-names>G</given-names></name><name><surname>Dupuis</surname><given-names>G</given-names></name><name><surname>Amrani</surname><given-names>A</given-names></name></person-group><article-title>Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>3638</fpage><lpage>3647</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.6.3638</pub-id><?supplied-pmid 17785799?><pub-id pub-id-type="pmid">17785799</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sainathan</surname><given-names>SK</given-names></name><name><surname>Hanna</surname><given-names>EM</given-names></name><name><surname>Gong</surname><given-names>Q</given-names></name><name><surname>Bishnupuri</surname><given-names>KS</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>FV</given-names></name><name><surname>Croze</surname><given-names>E</given-names></name><name><surname>Houchen</surname><given-names>C</given-names></name><name><surname>Anant</surname><given-names>S</given-names></name><name><surname>Dieckgraefe</surname><given-names>BK</given-names></name></person-group><article-title>Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis</article-title><source>Inflamm Bowel Dis</source><year>2008</year><volume>14</volume><fpage>88</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1002/ibd.20279</pub-id><?supplied-pmid 17932977?><pub-id pub-id-type="pmid">17932977</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>XO</given-names></name><name><surname>Chang</surname><given-names>SH</given-names></name><name><surname>Nurieva</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hood</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Tian</surname><given-names>Q</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name></person-group><article-title>A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><fpage>1133</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1038/ni1261</pub-id><?supplied-pmid 16200068?><pub-id pub-id-type="pmid">16200068</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goverman</surname><given-names>J</given-names></name></person-group><article-title>Autoimmune T cell responses in the central nervous system</article-title><source>Nat Rev Immunol</source><year>2009</year><volume>9</volume><fpage>393</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1038/nri2550</pub-id><?supplied-pmid 19444307?><pub-id pub-id-type="pmid">19444307</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrella</surname><given-names>O</given-names></name><name><surname>Carrieri</surname><given-names>PB</given-names></name><name><surname>De Mercato</surname><given-names>R</given-names></name><name><surname>Buscaino</surname><given-names>GA</given-names></name></person-group><article-title>Markers of activated T lymphocytes and T cell receptor gamma/delta+ in patients with multiple sclerosis</article-title><source>Eur Neurol</source><year>1993</year><volume>33</volume><fpage>152</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1159/000116923</pub-id><?supplied-pmid 8467823?><pub-id pub-id-type="pmid">8467823</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQualter</surname><given-names>JL</given-names></name><name><surname>Darwiche</surname><given-names>R</given-names></name><name><surname>Ewing</surname><given-names>C</given-names></name><name><surname>Onuki</surname><given-names>M</given-names></name><name><surname>Kay</surname><given-names>TW</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name><name><surname>Reid</surname><given-names>HH</given-names></name><name><surname>Bernard</surname><given-names>CC</given-names></name></person-group><article-title>Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis</article-title><source>J Exp Med</source><year>2001</year><volume>194</volume><fpage>873</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1084/jem.194.7.873</pub-id><?supplied-pmid 11581310?><pub-id pub-id-type="pmid">11581310</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponomarev</surname><given-names>ED</given-names></name><name><surname>Shriver</surname><given-names>LP</given-names></name><name><surname>Maresz</surname><given-names>K</given-names></name><name><surname>Pedras-Vasconcelos</surname><given-names>J</given-names></name><name><surname>Verthelyi</surname><given-names>D</given-names></name><name><surname>Dittel</surname><given-names>BN</given-names></name></person-group><article-title>GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis</article-title><source>J Immunol</source><year>2007</year><volume>178</volume><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.1.39</pub-id><?supplied-pmid 17182538?><pub-id pub-id-type="pmid">17182538</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#225;lez</surname><given-names>H</given-names></name><name><surname>Pacheco</surname><given-names>R</given-names></name></person-group><article-title>T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases</article-title><source>J Neuroinflammation</source><year>2014</year><volume>11</volume><fpage>201</fpage><pub-id pub-id-type="doi">10.1186/s12974-014-0201-8</pub-id><?supplied-pmid 25441979?><pub-id pub-id-type="pmid">25441979</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parajuli</surname><given-names>B</given-names></name><name><surname>Sonobe</surname><given-names>Y</given-names></name><name><surname>Kawanokuchi</surname><given-names>J</given-names></name><name><surname>Doi</surname><given-names>Y</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Takeuchi</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>T</given-names></name><name><surname>Suzumura</surname><given-names>A</given-names></name></person-group><article-title>GM-CSF increases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia</article-title><source>J Neuroinflammation</source><year>2012</year><volume>9</volume><fpage>268</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-9-268</pub-id><?supplied-pmid 23234315?><pub-id pub-id-type="pmid">23234315</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>IL</given-names></name><name><surname>Dickendesher</surname><given-names>TL</given-names></name><name><surname>Segal</surname><given-names>BM</given-names></name></person-group><article-title>Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>3190</fpage><lpage>3197</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-07-168575</pub-id><?supplied-pmid 19196868?><pub-id pub-id-type="pmid">19196868</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aub&#233;</surname><given-names>B</given-names></name><name><surname>L&#233;vesque</surname><given-names>SA</given-names></name><name><surname>Par&#233;</surname><given-names>A</given-names></name><name><surname>Chamma</surname><given-names>&#201;</given-names></name><name><surname>K&#233;bir</surname><given-names>H</given-names></name><name><surname>Gorina</surname><given-names>R</given-names></name><name><surname>L&#233;cuyer</surname><given-names>MA</given-names></name><name><surname>Alvarez</surname><given-names>JI</given-names></name><name><surname>De Koninck</surname><given-names>Y</given-names></name><name><surname>Engelhardt</surname><given-names>B</given-names></name><etal/></person-group><article-title>Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases</article-title><source>J Immunol</source><year>2014</year><volume>193</volume><fpage>2438</fpage><lpage>2454</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400401</pub-id><?supplied-pmid 25049355?><pub-id pub-id-type="pmid">25049355</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>MJ</given-names></name><name><surname>Doose</surname><given-names>JM</given-names></name><name><surname>Melchior</surname><given-names>B</given-names></name><name><surname>Schmid</surname><given-names>CD</given-names></name><name><surname>Ploix</surname><given-names>CC</given-names></name></person-group><article-title>CNS immune privilege: hiding in plain sight</article-title><source>Immunol Rev</source><year>2006</year><volume>213</volume><fpage>48</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2006.00441.x</pub-id><?supplied-pmid 16972896?><pub-id pub-id-type="pmid">16972896</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirota</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Yoshitomi</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Sakaguchi</surname><given-names>N</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis</article-title><source>J Exp Med</source><year>2007</year><volume>204</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1084/jem.20062259</pub-id><?supplied-pmid 17227914?><pub-id pub-id-type="pmid">17227914</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakae</surname><given-names>S</given-names></name><name><surname>Nambu</surname><given-names>A</given-names></name><name><surname>Sudo</surname><given-names>K</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name></person-group><article-title>Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>6173</fpage><lpage>6177</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.11.6173</pub-id><?supplied-pmid 14634133?><pub-id pub-id-type="pmid">14634133</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellner</surname><given-names>H</given-names></name></person-group><article-title>Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential</article-title><source>Ther Adv Musculoskelet Dis</source><year>2013</year><volume>5</volume><fpage>141</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1177/1759720X13485328</pub-id><?supplied-pmid 23858337?><pub-id pub-id-type="pmid">23858337</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>WD</given-names></name><name><surname>Firestein</surname><given-names>GS</given-names></name><name><surname>Taetle</surname><given-names>R</given-names></name><name><surname>Kaushansky</surname><given-names>K</given-names></name><name><surname>Zvaifler</surname><given-names>NJ</given-names></name></person-group><article-title>Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions</article-title><source>J Clin Invest</source><year>1989</year><volume>83</volume><fpage>876</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1172/JCI113971</pub-id><?supplied-pmid 2646320?><pub-id pub-id-type="pmid">2646320</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiehn</surname><given-names>C</given-names></name><name><surname>Wermann</surname><given-names>M</given-names></name><name><surname>Pezzutto</surname><given-names>A</given-names></name><name><surname>H&#252;fner</surname><given-names>M</given-names></name><name><surname>Heilig</surname><given-names>B</given-names></name></person-group><article-title>Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy</article-title><source>Z Rheumatol</source><year>1992</year><volume>51</volume><fpage>121</fpage><lpage>126</lpage><?supplied-pmid 1502858?><pub-id pub-id-type="pmid">1502858</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazenberg</surname><given-names>BP</given-names></name><name><surname>Van Leeuwen</surname><given-names>MA</given-names></name><name><surname>Van Rijswijk</surname><given-names>MH</given-names></name><name><surname>Stern</surname><given-names>AC</given-names></name><name><surname>Vellenga</surname><given-names>E</given-names></name></person-group><article-title>Correction of granulocytopenia in Felty&#8217;s syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis</article-title><source>Blood</source><year>1989</year><volume>74</volume><fpage>2769</fpage><lpage>2770</lpage><?supplied-pmid 2510837?><pub-id pub-id-type="pmid">2510837</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotake</surname><given-names>S</given-names></name><name><surname>Higaki</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Himeno</surname><given-names>S</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>KJ</given-names></name><name><surname>Nara</surname><given-names>N</given-names></name><name><surname>Miyasaka</surname><given-names>N</given-names></name><name><surname>Nishioka</surname><given-names>K</given-names></name><name><surname>Kashiwazaki</surname><given-names>S</given-names></name></person-group><article-title>Detection of myeloid precursors (granulocyte/macrophage colony forming units) in the bone marrow adjacent to rheumatoid arthritis joints</article-title><source>J Rheumatol</source><year>1992</year><volume>19</volume><fpage>1511</fpage><lpage>1516</lpage><?supplied-pmid 1464860?><pub-id pub-id-type="pmid">1464860</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menaa</surname><given-names>C</given-names></name><name><surname>Kurihara</surname><given-names>N</given-names></name><name><surname>Roodman</surname><given-names>GD</given-names></name></person-group><article-title>CFU-GM-derived cells form osteoclasts at a very high efficiency</article-title><source>Biochem Biophys Res Commun</source><year>2000</year><volume>267</volume><fpage>943</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1999.2042</pub-id><?supplied-pmid 10673396?><pub-id pub-id-type="pmid">10673396</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piper</surname><given-names>C</given-names></name><name><surname>Pesenacker</surname><given-names>AM</given-names></name><name><surname>Bending</surname><given-names>D</given-names></name><name><surname>Thirugnanabalan</surname><given-names>B</given-names></name><name><surname>Varsani</surname><given-names>H</given-names></name><name><surname>Wedderburn</surname><given-names>LR</given-names></name><name><surname>Nistala</surname><given-names>K</given-names></name></person-group><article-title>T cell expression of granulocyte-macrophage colony-stimulating factor in juvenile arthritis is contingent upon Th17 plasticity</article-title><source>Arthritis Rheumatol</source><year>2014</year><volume>66</volume><fpage>1955</fpage><lpage>1960</lpage><pub-id pub-id-type="doi">10.1002/art.38647</pub-id><?supplied-pmid 24692225?><pub-id pub-id-type="pmid">24692225</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>IK</given-names></name><name><surname>Bendele</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>DA</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name></person-group><article-title>Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice</article-title><source>Ann Rheum Dis</source><year>1997</year><volume>56</volume><fpage>364</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1136/ard.56.6.364</pub-id><?supplied-pmid 9227165?><pub-id pub-id-type="pmid">9227165</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Hirota</surname><given-names>K</given-names></name><name><surname>Yoshitomi</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Teradaira</surname><given-names>S</given-names></name><name><surname>Akizuki</surname><given-names>S</given-names></name><name><surname>Prieto-Martin</surname><given-names>P</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>N</given-names></name><name><surname>Kohl</surname><given-names>J</given-names></name><etal/></person-group><article-title>Complement drives Th17 cell differentiation and triggers autoimmune arthritis</article-title><source>J Exp Med</source><year>2010</year><volume>207</volume><fpage>1135</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1084/jem.20092301</pub-id><?supplied-pmid 20457757?><pub-id pub-id-type="pmid">20457757</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keith</surname><given-names>RC</given-names></name><name><surname>Powers</surname><given-names>JL</given-names></name><name><surname>Redente</surname><given-names>EF</given-names></name><name><surname>Sergew</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>RJ</given-names></name><name><surname>Gizinski</surname><given-names>A</given-names></name><name><surname>Holers</surname><given-names>VM</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Riches</surname><given-names>DW</given-names></name></person-group><article-title>A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice</article-title><source>Exp Lung Res</source><year>2012</year><volume>38</volume><fpage>55</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.3109/01902148.2011.636139</pub-id><?supplied-pmid 22185348?><pub-id pub-id-type="pmid">22185348</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>GR</given-names></name><name><surname>Gonda</surname><given-names>TJ</given-names></name><name><surname>Metcalf</surname><given-names>D</given-names></name><name><surname>Hariharan</surname><given-names>IK</given-names></name><name><surname>Cory</surname><given-names>S</given-names></name></person-group><article-title>A lethal myeloproliferative syndrome in mice transplanted with bone marrow cells infected with a retrovirus expressing granulocyte-macrophage colony stimulating factor</article-title><source>EMBO J</source><year>1989</year><volume>8</volume><fpage>441</fpage><lpage>448</lpage><?supplied-pmid 2542015?><pub-id pub-id-type="pmid">2542015</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>Z</given-names></name><name><surname>Ohkawara</surname><given-names>Y</given-names></name><name><surname>Jordana</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>F</given-names></name><name><surname>Gauldie</surname><given-names>J</given-names></name></person-group><article-title>Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions</article-title><source>J Clin Invest</source><year>1996</year><volume>97</volume><fpage>1102</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1172/JCI118503</pub-id><?supplied-pmid 8613534?><pub-id pub-id-type="pmid">8613534</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>ES</given-names></name><name><surname>Lazar</surname><given-names>MH</given-names></name><name><surname>Thannickal</surname><given-names>VJ</given-names></name></person-group><article-title>Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis</article-title><source>J Pathol</source><year>2003</year><volume>201</volume><fpage>343</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1002/path.1446</pub-id><?supplied-pmid 14595745?><pub-id pub-id-type="pmid">14595745</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>JG</given-names></name><name><surname>Parhami</surname><given-names>N</given-names></name><name><surname>Killam</surname><given-names>D</given-names></name><name><surname>Garcia</surname><given-names>PL</given-names></name><name><surname>Keogh</surname><given-names>BA</given-names></name></person-group><article-title>Bronchoalveolar lavage fluid evaluation in rheumatoid arthritis</article-title><source>Am Rev Respir Dis</source><year>1986</year><volume>133</volume><fpage>450</fpage><lpage>454</lpage><?supplied-pmid 3485395?><pub-id pub-id-type="pmid">3485395</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>JG</given-names></name><name><surname>James</surname><given-names>HL</given-names></name><name><surname>Zinkgraf</surname><given-names>S</given-names></name><name><surname>Perlman</surname><given-names>MB</given-names></name><name><surname>Keogh</surname><given-names>BA</given-names></name></person-group><article-title>Lower respiratory tract abnormalities in rheumatoid interstitial lung disease. Potential role of neutrophils in lung injury</article-title><source>Am Rev Respir Dis</source><year>1987</year><volume>136</volume><fpage>811</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1164/ajrccm/136.4.811</pub-id><?supplied-pmid 2821854?><pub-id pub-id-type="pmid">2821854</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>Z</given-names></name><name><surname>Braciak</surname><given-names>T</given-names></name><name><surname>Ohkawara</surname><given-names>Y</given-names></name><name><surname>Sallenave</surname><given-names>JM</given-names></name><name><surname>Foley</surname><given-names>R</given-names></name><name><surname>Sime</surname><given-names>PJ</given-names></name><name><surname>Jordana</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>FL</given-names></name><name><surname>Gauldie</surname><given-names>J</given-names></name></person-group><article-title>Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation</article-title><source>J Leukoc Biol</source><year>1996</year><volume>59</volume><fpage>481</fpage><lpage>488</lpage><?supplied-pmid 8613693?><pub-id pub-id-type="pmid">8613693</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>H</given-names></name><name><surname>Katoh</surname><given-names>S</given-names></name><name><surname>Kadota</surname><given-names>J</given-names></name><name><surname>Matsubara</surname><given-names>Y</given-names></name><name><surname>Fukushima</surname><given-names>K</given-names></name><name><surname>Mukae</surname><given-names>H</given-names></name><name><surname>Matsukura</surname><given-names>S</given-names></name><name><surname>Kohno</surname><given-names>S</given-names></name></person-group><article-title>Interleukin 5 and granulocyte-macrophage colony-stimulating factor levels in bronchoalveolar lavage fluid in interstitial lung disease</article-title><source>Eur Respir J</source><year>2000</year><volume>16</volume><fpage>959</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1183/09031936.00.16595900</pub-id><?supplied-pmid 11153599?><pub-id pub-id-type="pmid">11153599</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>C</given-names></name><name><surname>Bauer</surname><given-names>W</given-names></name><name><surname>Braun</surname><given-names>RK</given-names></name><name><surname>Menz</surname><given-names>G</given-names></name><name><surname>Braun</surname><given-names>P</given-names></name><name><surname>Schwarz</surname><given-names>F</given-names></name><name><surname>Hansel</surname><given-names>TT</given-names></name><name><surname>Villiger</surname><given-names>B</given-names></name></person-group><article-title>Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia</article-title><source>Am J Respir Crit Care Med</source><year>1994</year><volume>150</volume><fpage>1038</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.150.4.7921434</pub-id><?supplied-pmid 7921434?><pub-id pub-id-type="pmid">7921434</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><mixed-citation publication-type="other">Izumi K, Hashizume M, Yoshimoto K, Kaneko Y, Yasuoka H, Suzuki K, Yamaoka K, Takeuchi Y. Serum GM-CSF levels are significantly associated with interstitial pneumonia in biologic-native patients with rheumatoid arthritis: a single-center prospective cohort study (Keio First-bio cohort study). In EULAR 2015. Roma: 2015</mixed-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernasconi</surname><given-names>E</given-names></name><name><surname>Favre</surname><given-names>L</given-names></name><name><surname>Maillard</surname><given-names>MH</given-names></name><name><surname>Bachmann</surname><given-names>D</given-names></name><name><surname>Pythoud</surname><given-names>C</given-names></name><name><surname>Bouzourene</surname><given-names>H</given-names></name><name><surname>Croze</surname><given-names>E</given-names></name><name><surname>Velichko</surname><given-names>S</given-names></name><name><surname>Parkinson</surname><given-names>J</given-names></name><name><surname>Michetti</surname><given-names>P</given-names></name><name><surname>Velin</surname><given-names>D</given-names></name></person-group><article-title>Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing</article-title><source>Inflamm Bowel Dis</source><year>2010</year><volume>16</volume><fpage>428</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1002/ibd.21072</pub-id><?supplied-pmid 19639560?><pub-id pub-id-type="pmid">19639560</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#228;britz</surname><given-names>J</given-names></name></person-group><article-title>Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn&#8217;s disease</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2014</year><volume>306</volume><fpage>G455</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00409.2013</pub-id><?supplied-pmid 24503766?><pub-id pub-id-type="pmid">24503766</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gennari</surname><given-names>R</given-names></name><name><surname>Alexander</surname><given-names>JW</given-names></name><name><surname>Gianotti</surname><given-names>L</given-names></name><name><surname>Eaves-Pyles</surname><given-names>T</given-names></name><name><surname>Hartmann</surname><given-names>S</given-names></name></person-group><article-title>Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by improving gut barrier function and modulating bacterial clearance</article-title><source>Ann Surg</source><year>1994</year><volume>220</volume><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1097/00000658-199407000-00010</pub-id><?supplied-pmid 8024361?><pub-id pub-id-type="pmid">8024361</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khor</surname><given-names>B</given-names></name><name><surname>Gardet</surname><given-names>A</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name></person-group><article-title>Genetics and pathogenesis of inflammatory bowel disease</article-title><source>Nature</source><year>2011</year><volume>474</volume><fpage>307</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1038/nature10209</pub-id><?supplied-pmid 21677747?><pub-id pub-id-type="pmid">21677747</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noguchi</surname><given-names>M</given-names></name><name><surname>Hiwatashi</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>ZX</given-names></name><name><surname>Toyota</surname><given-names>T</given-names></name></person-group><article-title>Increased secretion of granulocyte-macrophage colony-stimulating factor in mucosal lesions of inflammatory bowel disease</article-title><source>Digestion</source><year>2001</year><volume>63</volume><issue>Suppl 1</issue><fpage>32</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1159/000051908</pub-id><?supplied-pmid 11173907?><pub-id pub-id-type="pmid">11173907</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ina</surname><given-names>K</given-names></name><name><surname>Kusugami</surname><given-names>K</given-names></name><name><surname>Hosokawa</surname><given-names>T</given-names></name><name><surname>Imada</surname><given-names>A</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Ohsuga</surname><given-names>M</given-names></name><name><surname>Kyokane</surname><given-names>K</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><name><surname>Nishio</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in inflammatory bowel disease</article-title><source>J Gastroenterol Hepatol</source><year>1999</year><volume>14</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1746.1999.01807.x</pub-id><?supplied-pmid 10029277?><pub-id pub-id-type="pmid">10029277</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dieleman</surname><given-names>LA</given-names></name><name><surname>Ridwan</surname><given-names>BU</given-names></name><name><surname>Tennyson</surname><given-names>GS</given-names></name><name><surname>Beagley</surname><given-names>KW</given-names></name><name><surname>Bucy</surname><given-names>RP</given-names></name><name><surname>Elson</surname><given-names>CO</given-names></name></person-group><article-title>Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice</article-title><source>Gastroenterology</source><year>1994</year><volume>107</volume><fpage>1643</fpage><lpage>1652</lpage><?supplied-pmid 7958674?><pub-id pub-id-type="pmid">7958674</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Jurickova</surname><given-names>I</given-names></name><name><surname>Koch</surname><given-names>D</given-names></name><name><surname>Willson</surname><given-names>T</given-names></name><name><surname>Samson</surname><given-names>C</given-names></name><name><surname>Bonkowski</surname><given-names>E</given-names></name><name><surname>Trauernicht</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>MO</given-names></name><name><surname>Tomer</surname><given-names>G</given-names></name><etal/></person-group><article-title>Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn&#8217;s disease</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><fpage>1261</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.12.046</pub-id><?supplied-pmid 19230854?><pub-id pub-id-type="pmid">19230854</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Hunt</surname><given-names>NH</given-names></name><name><surname>Bao</surname><given-names>S</given-names></name></person-group><article-title>The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation</article-title><source>Cell Res</source><year>2008</year><volume>18</volume><fpage>1220</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.310</pub-id><?supplied-pmid 19030026?><pub-id pub-id-type="pmid">19030026</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egea</surname><given-names>L</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Kagnoff</surname><given-names>MF</given-names></name></person-group><article-title>GM-CSF: a role in immune and inflammatory reactions in the intestine</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2010</year><volume>4</volume><fpage>723</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1586/egh.10.73</pub-id><?supplied-pmid 21108592?><pub-id pub-id-type="pmid">21108592</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khajah</surname><given-names>M</given-names></name><name><surname>Millen</surname><given-names>B</given-names></name><name><surname>Cara</surname><given-names>DC</given-names></name><name><surname>Waterhouse</surname><given-names>C</given-names></name><name><surname>McCafferty</surname><given-names>DM</given-names></name></person-group><article-title>Granulocyte-macrophage colony-stimulating factor (GM-CSF): a chemoattractive agent for murine leukocytes in vivo</article-title><source>J Leukoc Biol</source><year>2011</year><volume>89</volume><fpage>945</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1189/jlb.0809546</pub-id><?supplied-pmid 21393420?><pub-id pub-id-type="pmid">21393420</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griseri</surname><given-names>T</given-names></name><name><surname>McKenzie</surname><given-names>BS</given-names></name><name><surname>Schiering</surname><given-names>C</given-names></name><name><surname>Powrie</surname><given-names>F</given-names></name></person-group><article-title>Dysregulated hematopoietic stem and progenitor cell activity promotes interleukin-23-driven chronic intestinal inflammation</article-title><source>Immunity</source><year>2012</year><volume>37</volume><fpage>1116</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.08.025</pub-id><?supplied-pmid 23200826?><pub-id pub-id-type="pmid">23200826</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biondo</surname><given-names>M</given-names></name><name><surname>Nasa</surname><given-names>Z</given-names></name><name><surname>Marshall</surname><given-names>A</given-names></name><name><surname>Toh</surname><given-names>BH</given-names></name><name><surname>Alderuccio</surname><given-names>F</given-names></name></person-group><article-title>Local transgenic expression of granulocyte macrophage-colony stimulating factor initiates autoimmunity</article-title><source>J Immunol</source><year>2001</year><volume>166</volume><fpage>2090</fpage><lpage>2099</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.166.3.2090</pub-id><?supplied-pmid 11160260?><pub-id pub-id-type="pmid">11160260</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dieckgraefe</surname><given-names>BK</given-names></name><name><surname>Korzenik</surname><given-names>JR</given-names></name></person-group><article-title>Treatment of active Crohn&#8217;s disease with recombinant human granulocyte-macrophage colony-stimulating factor</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>1478</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)11437-1</pub-id><?supplied-pmid 12433518?><pub-id pub-id-type="pmid">12433518</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korzenik</surname><given-names>JR</given-names></name><name><surname>Dieckgraefe</surname><given-names>BK</given-names></name><name><surname>Valentine</surname><given-names>JF</given-names></name><name><surname>Hausman</surname><given-names>DF</given-names></name><name><surname>Gilbert</surname><given-names>MJ</given-names></name></person-group><article-title>Group SiCsDS: sargramostim for active Crohn&#8217;s disease</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>2193</fpage><lpage>2201</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa041109</pub-id><?supplied-pmid 15917384?><pub-id pub-id-type="pmid">15917384</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valentine</surname><given-names>JF</given-names></name><name><surname>Fedorak</surname><given-names>RN</given-names></name><name><surname>Feagan</surname><given-names>B</given-names></name><name><surname>Fredlund</surname><given-names>P</given-names></name><name><surname>Schmitt</surname><given-names>R</given-names></name><name><surname>Ni</surname><given-names>P</given-names></name><name><surname>Humphries</surname><given-names>TJ</given-names></name></person-group><article-title>Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn&#8217;s disease: a randomised, double-blind, placebo-controlled, phase 2 study</article-title><source>Gut</source><year>2009</year><volume>58</volume><fpage>1354</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1136/gut.2008.165738</pub-id><?supplied-pmid 19505878?><pub-id pub-id-type="pmid">19505878</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>L</given-names></name><name><surname>MacDonald</surname><given-names>JK</given-names></name><name><surname>McDonald</surname><given-names>JW</given-names></name><name><surname>Chande</surname><given-names>N</given-names></name></person-group><article-title>Sargramostim (GM-CSF) for induction of remission in Crohn&#8217;s disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials</article-title><source>Inflamm Bowel Dis</source><year>2012</year><volume>18</volume><fpage>1333</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1002/ibd.22973</pub-id><?supplied-pmid 22552871?><pub-id pub-id-type="pmid">22552871</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantinescu</surname><given-names>CS</given-names></name><name><surname>Asher</surname><given-names>A</given-names></name><name><surname>Fryze</surname><given-names>W</given-names></name><name><surname>Kozubski</surname><given-names>W</given-names></name><name><surname>Wagner</surname><given-names>F</given-names></name><name><surname>Aram</surname><given-names>J</given-names></name><name><surname>Tanasescu</surname><given-names>R</given-names></name><name><surname>Korolkiewicz</surname><given-names>RP</given-names></name><name><surname>Dirnberger-Hertweck</surname><given-names>M</given-names></name><name><surname>Steidl</surname><given-names>S</given-names></name><etal/></person-group><article-title>Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis</article-title><source>Neurol Neuroimmunol Neuroinflamm</source><year>2015</year><volume>2</volume><fpage>e117</fpage><pub-id pub-id-type="doi">10.1212/NXI.0000000000000117</pub-id><?supplied-pmid 26185773?><pub-id pub-id-type="pmid">26185773</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><mixed-citation publication-type="other">Behrens F, Tak PP, Ostergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A, et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015;74(6):1058&#8211;64. doi:10.1136/annrheumdis-2013-204816. Epub 2014 Feb 17.</mixed-citation></ref><ref id="CR117"><label>117.</label><mixed-citation publication-type="other">Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2013;72(9):1445&#8211;52. doi:10.1136/annrheumdis-2012-202450. Epub 2012 Dec 12.</mixed-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Nakata</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Luisetti</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Koch</surname><given-names>DE</given-names></name><name><surname>Stevens</surname><given-names>CA</given-names></name><name><surname>Beck</surname><given-names>DC</given-names></name><name><surname>Denson</surname><given-names>LA</given-names></name><name><surname>Carey</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>2547</fpage><lpage>2556</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-05-155689</pub-id><?supplied-pmid 19282464?><pub-id pub-id-type="pmid">19282464</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakagami</surname><given-names>T</given-names></name><name><surname>Beck</surname><given-names>D</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Carey</surname><given-names>BC</given-names></name><name><surname>Nakata</surname><given-names>K</given-names></name><name><surname>Keller</surname><given-names>G</given-names></name><name><surname>Wood</surname><given-names>RE</given-names></name><name><surname>Wert</surname><given-names>SE</given-names></name><name><surname>Ikegami</surname><given-names>M</given-names></name><etal/></person-group><article-title>Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>182</volume><fpage>49</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1164/rccm.201001-0008OC</pub-id><?supplied-pmid 20224064?><pub-id pub-id-type="pmid">20224064</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Egea</surname><given-names>L</given-names></name><name><surname>Dann</surname><given-names>SM</given-names></name><name><surname>Eckmann</surname><given-names>L</given-names></name><name><surname>Kagnoff</surname><given-names>MF</given-names></name></person-group><article-title>GM-CSF-facilitated dendritic cell recruitment and survival govern the intestinal mucosal response to a mouse enteric bacterial pathogen</article-title><source>Cell Host Microbe</source><year>2010</year><volume>7</volume><fpage>151</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2010.01.006</pub-id><?supplied-pmid 20159620?><pub-id pub-id-type="pmid">20159620</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burmester</surname><given-names>GR</given-names></name><name><surname>Feist</surname><given-names>E</given-names></name><name><surname>Sleeman</surname><given-names>MA</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>White</surname><given-names>B</given-names></name><name><surname>Magrini</surname><given-names>F</given-names></name></person-group><article-title>Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-&#945;, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study</article-title><source>Ann Rheum Dis</source><year>2011</year><volume>70</volume><fpage>1542</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1136/ard.2010.146225</pub-id><?supplied-pmid 21613310?><pub-id pub-id-type="pmid">21613310</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burmester</surname><given-names>G</given-names></name><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Kremer</surname><given-names>JM</given-names></name><name><surname>Miranda</surname><given-names>P</given-names></name><name><surname>Korkosz</surname><given-names>M</given-names></name><name><surname>Vencovsky</surname><given-names>J</given-names></name><name><surname>Rubbert-Roth</surname><given-names>A</given-names></name><name><surname>Mysler</surname><given-names>E</given-names></name><name><surname>Sandbach</surname><given-names>S</given-names></name><name><surname>Sleeman</surname><given-names>MA</given-names></name><etal/></person-group><source>Efficacy and safety/tolerability of mavrilimumab, a human GM-CSFR&#195;&#161; monoclonal antibody in patients with rheumatoid arthritis</source><year>2014</year><publisher-loc>Boston</publisher-loc><publisher-name>American College of Rheumatology</publisher-name></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kremer</surname><given-names>JM</given-names></name><name><surname>Burmester</surname><given-names>G</given-names></name><name><surname>Weinblatt</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Karlsson</surname><given-names>N</given-names></name><name><surname>Godwood</surname><given-names>A</given-names></name><name><surname>Close</surname><given-names>D</given-names></name></person-group><source>Analysis of patient-reported outcomes during treatment with mavrilimumab, a human monoclonal antibody targeting GM-CSFR&#225;, in the randomized Phase 2b Earth Explorer 1 Study</source><year>2014</year><publisher-loc>Boston</publisher-loc><publisher-name>American College of Rheumatology</publisher-name></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Burmester</surname><given-names>G</given-names></name><name><surname>Kremer</surname><given-names>JM</given-names></name><name><surname>Miranda</surname><given-names>P</given-names></name><name><surname>Korkosz</surname><given-names>M</given-names></name><name><surname>Vencovsky</surname><given-names>J</given-names></name><name><surname>Rubbert-Roth</surname><given-names>A</given-names></name><name><surname>Mysler</surname><given-names>E</given-names></name><name><surname>Close</surname><given-names>D</given-names></name><name><surname>Sleeman</surname><given-names>MA</given-names></name><etal/></person-group><source>Rapid onset of clinical benefit is associated with a reduction in validated biomarkers of disease in patients with rheumatoid arthritis treated with mavrilimumab, a human monoclonal antibody targeting GM-CSFR&#195;&#161;</source><year>2014</year><publisher-loc>Boston</publisher-loc><publisher-name>American College of Rheumatology</publisher-name></element-citation></ref><ref id="CR125"><label>125.</label><mixed-citation publication-type="other">A study of mavrilimumab in subjects with moderate-to-severe rheumatoid arthritis. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01706926">https://clinicaltrials.gov/ct2/show/NCT01706926</ext-link>.</mixed-citation></ref><ref id="CR126"><label>126.</label><mixed-citation publication-type="other">A long term safety study of mavrilimumab in adult subjects with rheumatoid arthritis. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT01712399">https://clinicaltrials.gov/ct2/show/study/NCT01712399</ext-link>.</mixed-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burmester</surname><given-names>G</given-names></name><name><surname>McInnes</surname><given-names>I</given-names></name><name><surname>Kremer</surname><given-names>J</given-names></name><name><surname>Miranda</surname><given-names>P</given-names></name><name><surname>Vencovsk&#253;</surname><given-names>J</given-names></name><name><surname>Godwood</surname><given-names>A</given-names></name><name><surname>Albulescu</surname><given-names>M</given-names></name><name><surname>Close</surname><given-names>D</given-names></name><name><surname>Weinblatt</surname><given-names>M</given-names></name></person-group><source>Long-term safety and efficacy of mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor-&#945; (GM&#8211;CSFR-&#945;) monoclonal antibody, in patients with rheumatoid arthritis (RA)</source><year>2015</year><publisher-loc>San Francisco</publisher-loc><publisher-name>American College of Rheumatology</publisher-name></element-citation></ref><ref id="CR128"><label>128.</label><mixed-citation publication-type="other">A study of mavrilimumab versus anti tumor necrosis factor in subjects with rheumatoid arthritis. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT01715896">https://clinicaltrials.gov/ct2/show/study/NCT01715896</ext-link></mixed-citation></ref><ref id="CR129"><label>129.</label><mixed-citation publication-type="other">A trial to evaluate the safety and tolerability of namilumab (MT203) in patients with mild to moderate rheumatoid arthritis (PRIORA). <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT01317797">https://clinicaltrials.gov/ct2/show/study/NCT01317797</ext-link>.</mixed-citation></ref><ref id="CR130"><label>130.</label><mixed-citation publication-type="other">Dose finding study of namilumab in combination with methotrexate in participants with moderate to severe rheumatoid arthritis (RA). <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02379091">https://clinicaltrials.gov/ct2/show/NCT02379091</ext-link>.</mixed-citation></ref><ref id="CR131"><label>131.</label><mixed-citation publication-type="other">Namilumab vs adalimumab in participants with moderate to severe early rheumatoid arthritis inadequately responding to methotrexate (TELLUS). <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02393378">https://clinicaltrials.gov/ct2/show/NCT02393378</ext-link>.</mixed-citation></ref><ref id="CR132"><label>132.</label><mixed-citation publication-type="other">Efficacy and safety of namilumab (MT203) for plaque psoriasis. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02129777">https://clinicaltrials.gov/ct2/show/NCT02129777</ext-link>.</mixed-citation></ref><ref id="CR133"><label>133.</label><mixed-citation publication-type="other">Study of KB003 in biologics-inadequate rheumatoid arthritis. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/results/NCT00995449">https://clinicaltrials.gov/ct2/show/results/NCT00995449</ext-link>.</mixed-citation></ref><ref id="CR134"><label>134.</label><mixed-citation publication-type="other">Safety and tolerability of MORAb-022 in healthy and rheumatoid arthritis subjects. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01357759">https://clinicaltrials.gov/ct2/show/NCT01357759</ext-link>.</mixed-citation></ref></ref-list></back></article>